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Dr. Marino De Leon, Chairperson 
 
Lipotoxicity is a response to lipid overload that has been associated with cellular 
dysfunction leading to cellular death.   The mechanism of lipotoxicity and its impact on 
the nervous system is critical as it can lead to debilitating neurological conditions.  This 
study examines key cellular events induced by palmitic acid lipotoxicity (PA-LTx) in 
Schwann cells cultured in euglycemic and hyperglycemic conditions. The data show that 
immortalized Schwann cell (iSC), as well as primary Schwann cell (pSC) cultures 
exposed to elevated levels of PA induced an apoptotic cell death that is dose and time-
dependent.   
The earliest indication of cellular dysfunction was a decrease in Ca
++
 levels in 
the endoplasmic reticulum (ER, [Ca
++
] ER).  This decrease in [Ca
++
 ]ER was associated 
with a significant change in the expression of ER stress signature genes such as  CHOP, 
Xbp1 and GRP78.  In SC cultured in euglycemic conditions, lysosomal membrane 
destabilization preceded mitochondrial membrane depolarization, oxidative stress and 
caspase 3/7 activation. The release of cathepsin L and B were also observed with PA 
treatments.  However, in hyperglycemic SCs, PA-LTx induced- ER stress followed 
mitochondrial injury, oxidative stress, caspase 3/7 activation with a subsequent 
 
xviii 
lysosomal release of cathepsins.  Of interest is the observation that hyperglycemia was 
able to magnify SC injury resulting in an earlier and more severe cell death.     
Treatment of iSC cultures with the calcium chelator BAPTA-AM resulted in an 
increase in cell viability in iSC cultures. In addition, treatment with antioxidant MCI-
186 reduced oxidative stress and increased cell viability in both euglycemic and 
hyperglycemic SC exposed to PA.   Furthermore, PA-LTx was able to disrupt mRNA 
and protein levels of Peripheral Myelin protein 22 within the first 12hrs. Understanding 
the mechanism of lipotoxicity is of importance in order to bring innovative therapies to 















Fatty Acids’ Structure and Function 
 
Fatty acids (FAs) are carboxylic acids with hydrocarbon chains, usually 12-24 
carbons in length.  The classification into saturated or unsaturated FAs is based on the 
presence of double bonds.  Unsaturated FAs, such as docosahexanoic acid (DHA), have 
one or more double bonds in their hydrocarbon chain. On the other hand, saturated FAs, 
such as palmitic acid (PA), lack carbon double bonds resulting in a straight hydrocarbon 
tail.  The double carbon-carbon bond makes the unsaturated FAs more angled and 
flexible, while lack of it renders the saturated FA less pliable and more rigid.  
FAs are also grouped by their chain length.  Short chain FAs have a carbon tail 
that is fewer than 6 carbons, medium chain FAs have 6-11 carbons and long chain FAs 
(LCFAs) have 12 or more carbons in their tail.  LCSFAs are less soluble and more rigid, 
and their increase in chain length makes them critical factors in the development of 
diseases [1]. 
However, physiological normal levels of FAs are not deleterious to their 
surroundings.  FAs provide fuel for tissues and cells.  Cells and organs depend on the 
availability of adequate levels of FAs to carry out normal cellular functions and perform 
important and critical metabolic activities [2].   In addition to being essential 
components in the architecture and construction of cellular membranes, FAs are 
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associated with the makeup of secondary messengers needed for appropriate cellular 
signaling.  
The transportation of FAs to their adequate locations is facilitated by albumin, a 
predominant protein found in plasma.  Albumin binds to circulating FAs and transports 
them to adipocytes for proper energy storage or to tissue for energy utilization.  The 
utilization of FAs as an energy source requires their activation before proper metabolism 
can take place.  Fatty acyl CoA synthetase, the first enzyme in β oxidation, transforms 
FAs into fatty acyl CoA. Through protein carriers and other enzymes, such as carnitine 
palmitoyl transferase I/II and carnitine acylcarnitine translocase, acyl-CoA is taken up 
by the inner mitochondrial membrane and converted to acetyl-CoA in the mitochondrial 
matrix.  Acetyl-CoA enters the Krebs cycle to produce FADH and FADH2. These two 
molecules reach the mitochondrial electron transport chain to produce the energy 




































Figure 1.   Glucose and FA metabolism.  Glucose is converted to pyruvate and further 
modified to acetyl-CoA by pyruvate dehydrogenase complex (PDC).  Similarly, FAs are 
activated by fatty acyl CoA synthetase to produce acyl CoA .   Acyl CoA is transported 
into the mitochondria by carnitine palmitoyl transferase 1,2 (CPT), fatty acid translocase 
(CD36), and carnitine acylcarnitine translocase (CACT).  β oxidation of acyl-CoA results 
in the production of acetyl CoA.  The acetyl CoA produced by glucose and FAs  
advances to the tricarboxylic acid cycle (TCA) and concludes in the electron transport 






When excess levels of FAs are encountered by cells, the esterification process 
begins.  Cells are able to esterify FAs into triglycerides (TG) for proper energy storage.  
The acceptance of two activated fatty acyl CoA molecules to form diaglycerol phosphate 
begins the esterification process. The removal of phosphate and the addition of a third 
fatty acid is the last step to TG formation.  The formation of TG lipid droplets in the 
cytosol is suggested to be the first line of defense of non-adipose cells to prevent cellular 
dysfunction [5].   
In addition to energy generation, FAs also play a role in cellular membrane 
structure and can influence the overall performance of the cell.  An example of the 
importance of FAs in cellular membrane function is the composition of sphingomyelin, 
an important component of cellular membranes. Proper membrane structure is dependent 
on adequate levels of sphingomyelin.  Ceramide, made of a long chain FA attached to a 
sphingosine molecule, makes part of the sphingomyelin protein.  In this way, FAs also 
serve as vital constituents in the structure of cellular membranes.   
 
 
Fatty Acids and Obesity 
 
According to the World Health Organization, obesity has reached global epidemic 
proportions.  It is estimated that by the year 2015, approximately 2.3 billion adults will be 
overweight (BMI 25-30 kg/m
2
) and at least 700 million will be obese (BMI ≥ 30kg/m
2
) 
[6].  Between the years of 1980 to 2006, obesity rates among 6 to 11-year-olds have more 
than doubled and have tripled among 12 to 19-year-olds [7].   More alarming is that 
current global studies reveal that childhood obesity will continue to increase significantly 
[8-10].  Obesity has been strongly linked to the increase in risk for developing many 
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diseases such as cancers, cardiovascular disorders, neurodegenerative diseases and 
diabetes type 2.   A common feature found in obese individuals is elevated levels of 
circulatory fatty acids (FAs) [11-13]. 
Therefore, an elevation of FAs in the diet results in unbound free fatty acids 
(FFAs) circulating in the blood that can be toxic to the entire biological system.  Non-
adipose cells, such as neurons and Schwann cells, are vulnerable to sustained elevated 
levels of FFAs.   In addition, excessive TG deposition and FFA overload, similar to that 
observed in obese and diabetic individuals, can lead to cellular dysfunction and cellular 
death. The succession of pathological cellular responses triggered by chronic and 





Lipotoxicity and Saturated FAs 
 
LTx can be trigger by LCSFAs, which are considered to be among the most 
damaging in the FA family. Three decisive factors that may contribute to LCSFA LTx 
include 1) their difficulty in undergoing esterification, 2) their ability to form 
diaglycerides and toxic by products such as ceramide, a  key mediator of cytotoxicity and 
apoptosis, and 3)  their ability to compact in lipid membrane rafts, thus decreasing cell 
membrane fluidity leading to cellular membrane dysfunction [5, 24-30].   
Gelb and Kessler (1963) analyzed the influences of FA structure on esterification 
in the small intestine of male golden hamsters. The data demonstrated an inverse 
correlation between the length of the FA chain and the percentage of FA esterification.  
Possible explanations for the decrease in LCSFA esterification were 1) the requirement of 
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an extra step or additional enzymes in the esterification procedure, thus decreasing the 
efficiency of the cell to process LCSFAs, and 2) the possible preference in the 
esterification of certain FAs by the cell [25].  
The difficulty in FA esterification can lead to the generation of toxic molecules.  
Toxic byproducts of LCSFA, such as ceramide, have been reported in many 
neurodegenerative disorders [31-32].  A study conducted by Blaszquez et al. (2001) 
demonstrated that cortical astrocytes undergo apoptosis through de novo production of 
ceramide by FFAs, and the inhibition of ceramide by an inducer of AMP-activated 
protein kinase prevented cellular death [33].  Another study found that the production of 
ceramide by PA induced apoptosis through ER damage and caspase 3 independent 
pathways in a Schwann cell (SC) model.  Interestingly, this same study demonstrated that 
the inhibition of ceramide led to ER damage  and a caspase-3 dependent cell death 
pathway [34]. 
In neuronal growth factor differentiated pheochromocytoma (NGFDPC12) cells, 
previous work from our lab revealed that exposure to LCSFAs, such as PA and stearic 
acid, activated the lipotoxic response.  However, treatment with unsaturated acids, such 
as oleic or arachidonic acids, did not induce LTx [35]. 
 
 
Palmitic acid Lipotoxicity (PA-LTx) 
 
PA (C:16) is  a LCSFA predominantly found in high saturated  fat diets, such as 
the western diet [36-38].  PA is able to induce lipotoxicity (PA-LTx) that is more severe 
and deleterious on tissues and cells when compared to other FAs [35, 39-40]. Studies 
reported from our laboratory have demonstrated that NGFDPC12 cells undergo PA-LTx 
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that is caspase-independent and involved a significant increase in gene expression of fas 
ligand/receptor and pro-apoptotic members of the Bcl2 family.   The proposed 
mechanism of PA-LTx in  a neuronal cell model included the involvement of  lysosomal 
and mitochondrial dysfunction, caspase activation and an augmented state of cellular 













































Figure 2.  Mechanisms of PA-LTx in neuronal cell model. PA induces LTx in 
NGFDPC12 cells through mitochondrial dysfunction resulting in the increase of reactive 
oxidative species (ROS) and the activation of caspases. PA-LTx also results in lysosomes 

















In an attempt to discern the mechanisms of PA-LTx we focused our experiments 
in examining the cellular targets of PA. In specific, we examined PA’s ability to target 
certain cellular organelles such as the ER, mitochondria, and lysosomes  which may 

































Figure 3.  Saturated Fatty Acids’ induction of cellular injury. Saturated FAs are able to 
induce apoptosis through the activation of death receptors, such as Fas and Toll like 
receptor 4 (TLR4).  Death receptors damage cellular membranes and release ceramide, 
which can injure the mitochondria.  TLR4 is able to activate the transcription of NF-kB to 
upregulate a variety of pro-inflammatory cytokines .  SFA can also directly damage the 
endoplasmic reticulum (ER) and the lysosome to induce apoptosis. In addition, free 
cholesterol (FC), which can injure the mitochondria, elevates cholesteryl-esters (CE) 







Endoplasmic Reticulum (ER) 
The endoplasmic reticulum (ER) has many important cellular functions such as 
protein assembly, Ca
++ 
storage, and lipid synthesis.  All proteins are assembled by the 
ER; however, certain proteins enter the lumen of the ER and are folded, modified and 
transported to the golgi apparatus for vesicular release into the cytosol.  An improperly 
folded protein is held in the ER lumen for repair, modification or degradation.  
Chaperones, such as GRP78, assist in the quality control of assembled proteins by 1) 
facilitating protein conformation and 2) retaining and repairing misfolded proteins.     
The increase in misfolded proteins in the ER can damage or overload the ER 
resulting in the activation of the unfolded protein response (UPR) and the ER-associated 
degradation pathway [44-45].  The first line of defense is through activation of the 
unfolded response [44], which attempts to decrease the load to the ER by 1) increasing 
the transcription of chaperones to aid in protein folding and 2) activate factors that will 
reduce protein translation.  If the UPR does not decrease ER stress, the ER associated 
degradation pathway is activated.  In this pathway the misfolded proteins in the ER are 
released to the cytosol to be degraded by proteosomes [45].  
In addition to regulating protein folding, cellular signaling is also an important 
function of the ER.  Studies in the literature have shown that intracellular  Ca
++
 can 
control nuclear transport, mitochondrial oxidative metabolism, and other cell signaling 
activities [46-48].  However, inadequate levels of intracellular Ca
++ 
are able to activate 
pro-apoptotic factors within the cell.  Studies have demonstrated that significant ER 
overload induced the efflux of Ca
++
 from  the ER into the cytosol and resulted in the 
activation of pro-apoptotic pathways [49-52].   Exposure of hypothalamic cells to PA for 
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4 hrs was able to phosphorylate c-Jun N-terminal kinase (JNK) and damage the ER, 
leading to an upregulation of pro-apoptotic genes [51, 53-54].  
 Other studies have gone further and suggest that PA is able to directly injure the 
ER, resulting in apoptosis [24].  Research by Borradaile et al. (2006) revealed that 
elevated levels of PA are quickly (5 hrs) incorporated into ER lipid membrane rafts of 
Chinese hamster ovarian cells (CHO) leading to apoptosis.  Exposure of CHO to PA 
resulted in 1) a notable dilation of the ER membrane, 2) the increase in ER membrane 
rigidity and loss of ER membrane fluidity, and 3) a significant depletion of ER Ca
++
 
stores that led to significant levels of intracellular Ca
++
.  This study suggested that the 
activation of cell death pathways and cellular damage were consequences of the increase 
in cytosolic Ca
++
 levels due to ER damage  [24]. 
 
 
Mitochondria and ASCOS 
 
The primary task of the mitochondria is to metabolize molecules, such as glucose 
and pyruvate, and convert them into adenosine triphosphate (ATP) for cellular energy.  
Adequate levels of ATP are required for cellular reactions and signal transduction 
pathways critical for cell survival.  The process begins with the catabolism of glucose and 
FAs into acetyl-CoA, which enter the tricarboxilyc acid cycle in the mitochondrial matrix 
to produce NADH and FADH2.  The electron transport chain [3], uses NADH and 
FADH2 to pump H+ ions out of the matrix to create a proton gradient between the 
mitochondrial matrix and the intramembranous space [3].  Complex V of the 
mitochondrial ETC, also known as ATP synthase, allows the influx of H+ ions into the 
matrix causing a phosphorylative reaction and, thus, generating ATP.  During this 
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process, low levels of  reactive oxidative species (ROS) are produced by the occasional 
escape of electrons from the ETC [55].   Normally, the free radicals formed by the 
electrons are neutralized by mitochondrial superoxide dismutase or cytochrome c.  
However, a disruption in the ETC can  increase the release of numerous electrons  into 
the intramembranous space, leading to an interaction with other cellular elements, such as 
oxygen,  resulting in oxidative stress [56]. 
Mitochondrial dysfunction and the production of an augmented state of oxidative 
stress (ASCOS) has been suggested to be a key factor in the cellular damage produced by 
LCSFAs like PA [41, 57-58].   FAs induce ROS and reactive nitritive stress (RNS), 
stimulating lipid peroxidation.  The byproducts of lipid peroxidation, lipid peroxides, are 
known to damage lipids, proteins, and cellular DNA [59].  
Another mechanism of mitochondrial damage is through the activation of pro-
apoptotic proteins, such as Bax. The pro-apoptotic protein, Bax, is known to perforate the 
mitochondrial membrane resulting in mitochondrial injury.   The formation of pores in 
the mitochondrial membrane by Bax results in the release of cytochrome c into the 
cytosol.  Cytochrome c binds to apoptosis activating factor 1 (Apaf1), caspase 9, and 
deoxyadenosine triphosphate (dATP) to form the apoptosome.  The generation of the 
apoptosome is able to activate initiator caspases, inducing apoptosis [60-61].  
Interestingly, a study found that PA was able to activate a “Bax- mediated mitochondrial 
induced” apoptotic pathway in C2 C12 myotubes.  This study proposed the direct 
activation of Bax by PA.  The activation of Bax results in mitochondrial injury and the 
induction of the apoptotic pathway.  Furthermore, Bax SiRNA experiments found that 
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suppression of  the Bax gene decreases DNA fragmentation and caspase activation after 
PA exposure [62].  
Studies have suggested that the mitochondrion, and not the ER, is the critical 
component in the apoptotic pathway.   Hypothalamic neurons revealed that PA 
metabolism by the mitochondria was required to induce ER stress, active caspase-3 and 
trigger PA-LTx.  The importance of the mitochondria in PA-LTx was confirmed by 
studies demonstrating that a non-metabolizable form of PA, methylpalmitate, had no 
negative effects on hypocampal neurons [53].  Along these lines, studies from our lab 
demonstrated that bromo-palmitate, a non metabolizable palmitate analog, was unable to 
induce lipotoxic effects in NGFDPC12 cells [63].   
In addition, studies from our laboratory have demonstrated that PA increases the 
expression of BNIP3, a pro-apoptotic member of the Bcl-2 family, and Fas-R, a death 
receptor, that  led to mitochondrial membrane destabilization (MMD) and ROS 
production in NGFDPC12 cells.  Furthermore, caspase-3 activation and cleavage of 
lamin B and PARP confirmed PA-LTx to be apoptotic [64].    
 
 
Lysosomes and Cathepsin Activation 
 
Lysosomes are membrane-bound cellular organelles that contain hydrolytic 
enzymes, such as proteases, nucleases, and phopholipases, active in the lysosomal acidic 
environment (pH. of 4.5 to 5).  The function of the lysosomes is to digest 
macromolecules and  recycle cellular material.   Following lysosomal injury by ASCOS 
or lysosomotrophic agents, proteases are released into the cytosol and initiate cellular 
death pathways [65-66].   Proteases, such as cathepsin B, are stable at physiologic pH  
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levels for a couple of minutes to a full hour following their release from lysosomes, thus 
supporting their ability to cause cellular injury.    Lysosomal membrane destabilization 
(LMD) is the result of the cell’s reaction to insults, such as caspase activation, Bax/Bak  
induction and translocation to lysosomal membranes, and mitochondria-induced  
generation of ASCOS [67-69].  
Previous studies in our lab determined that LMD was an early event in PA-LTx.  
LMD led to the release of proteases into the cytosol resulting in cellular damage. In 
addition, the release of cathepsin L from the lysosomes was detected as early as 3 hours 
after PA exposure in NGFDPC12 cells and the inhibition of cathepsin L significantly 
eliminated MMD and apoptosis [41].   
Hepatocytes exposed to PA for 3 hours resulted in the activation and translocation 
of Bax to the lysosome that preceded MMD.  It was proposed that Bax’s  induction of 
LMD was independent of ceramide and caspase activation.  Furthermore, inhibition of  
Bax after PA treatment  1)  reduced LMD 2)  inhibited the release of cathepsin B and 3)  
increased cell viability, suggesting a significant role of the lysosome in PA-LTx [70].   
However the exact mechanism of lysosomal injury by PA continues to be unclear. 
 
 




 Over 20 million people suffer from PN, which is considered to be one of the most 
common and chronic diseases in the United States [75]. PN is a debilitating complication 
observed in obese and diabetic individuals [76-78].  A direct correlation between elevated 
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lipid levels and the occurrence of neuropathy in obese individuals has been observed in 
many studies [79-80].   
A significant number of people who are obese, but do not demonstrate overt 
diabetes, have demonstrated sensory neuropathy in the median, ulnar and sural nerves. In 
addition, they also exhibit a decrease in action potential amplitude in the tibial and 
peroneal nerves [81].  The development of PN in individuals who demonstrate metabolic 
lipid derangement without hyperglycemia suggest the possible role of FFAs in the 
induction of neuronal injury.   
 
 
Clinical Signs of Peripheral Nerve Injury 
 
Individuals suffering from peripheral neuropathy (PN) frequently suffer from 
altered sensations (dysesthesias and parasthesias) that progress to painful perceptions 
(hyperalgesias) and, in later stages, to extreme responses to non-painful stimuli 
(allodynia).  Axons will also be lost and result in muscle weakness and loss of motor 
function [71-72].  Studies in PN have determined that small myelinated and unmyelinated 





Recent studies are now discovering the relationship between dyslipidemia and its 
role in peripheral neuropathy.  Studies suggest that elevated and chronic levels of FFA’s, 
found in the pre-diabetic state, may exert detrimental and toxic effects on peripheral 
nerves [82].   A study performed by Andrea Vincent, found that in C57/BL6 mice that 
were fed a high fat diet, developed PN prior to the onset of hyperglycemia. These mice 
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exhibited high levels of systemic oxidative stress, plasma triglycerides, and FFAs.   
Plasma protein levels were found to be significantly oxidized, specifically low density 
lipoproteins (LDLs).  In addition, lectin-like oxidized low-density lipoprotein receptor- 1 
(LOX-1), a receptor for oxidized LDLs (oxLDLs) known to increase oxidative stress in 
endothelial cells, was also observed to be activated in the membranes of dorsal root 
ganglions (DRGs) [83-84].  Upon closer examination, it was found that exposure of 
oxLDLs to cultured DRGs from mice fed a high fat diet stimulated LOX-1 activity, 
increased mitochondrial superoxide levels, and activated caspase 3.  Furthermore, the 
inhibition of nicotinamide adenine dinucleotide phosphate-oxidase (NAD(P)H) oxidase, 
an enzyme that produces superoxide, was able to prevent injury to  DRGs.   However, 
inhibition of NAD(P)H did not prevent DRG death in an elevated FFA and 
hyperglycemic environment.  The findings elucidated the different death mechanisms 
activated by the cell when it encounters a hyperglycemic condition in combination with a 
high FA environment [84].   
The physiological stress of a hyperglycemic and/or an LTx environment is able to 
injure many of the surrounding tissues.  Schwann cells (SC), the glial cells of the 
peripheral nervous system, undergo dysfunction leading to demyelination and axonal 
atrophy, which are prominent abnormalities associated with peripheral neuropathies and 
axon degeneration [85-87].  Damage to SCs leads to dysfunctions in nerve conduction 
velocities, axonal atrophy, and axonal degeneration [88-90].  Suzuki et al. (2011) 
examined the role of ceramide in the activation of apoptosis in an immortalized SC (iSC) 
clone [78].   iSC clones were exposed to PA: Bovine Serum Albumin (BSA) 2:1 
(500µM:250µM) for 48 hours which resulted in apoptosis, an increase in ceramide levels, 
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caspase 3 activation, and the production of ER stress.  It was found that ceramide, 
through PA or de novo synthesis, was able to induce apoptosis through a caspase 3 
independent pathway since inhibition of caspase 3 did not completely restore  iSC 
viability.  Interestingly, inhibition of ceramide did not prevent caspase 3 activation, ER 
stress, and cellular death [34].  This study suggested that PA may directly induce cellular 
injury without ceramide production through the activation of caspase 3 [91-92].    
 
 
Diabetic Peripheral Neuropathy 
 
Out of all cases of peripheral neuropathies, 60-70% are related to diabetes [75, 
93].  Diabetes affects approximately 189 million people worldwide, and it is estimated 
that by the year 2025, there will be 324 million people affected with this disorder [94].  A 
strong link has been established between peripheral neuropathy and the development of 
foot ulcers [95].   Studies have shown that approximately 25% of diabetics will develop 
neuropathy that will result in foot ulcers, and more than half will become infected and 
require hospitalization. Furthermore, one in 5 cases of foot ulcers will require some form 
of amputation with approximately 50% of the patients requiring a second amputation 
after 2 years of the first one.  After a limb amputation, the mortality rate of individuals 
with diabetes type 2 increases to approximately 50% [95-97].  
 
 
Clinical Signs of Diabetic Peripheral Neuropathy 
 
Diabetic peripheral neuropathy (DPN) commonly presents with the loss of 
sensation in a “stock and glove” pattern [98]. The first symptoms usually begin in the feet 
and ascend through the lower extremities, followed by impairment in the hands that will 
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progress proximately [77, 99].   The decrease in nerve conduction velocity, which is 
pathognomonic for DPN, is frequently asymptomatic  [100].   Individuals with DPN will 
also develop dysesthesias and parasthesias that will progress to hyperalgesias and, in later 
stages, allodynia.  Muscle weakness and loss of motor function will be observed at later 
stages [71-72].   
 
 
Mechanisms of DPN: Hyperglycemia 
 
It is difficult to suggest that DPN is caused by a single insult due to the 
multifactorial components found in diabetes.  Hyperglycemia, elevated levels of FFA’s, a 
decrease in neuronal blood flow, oxidative stress, and an altered growth factor level are 
some of the causative factors implicated in peripheral nerve injury [67-70, [101].   
Hyperglycemia has been the major focus of many studies in the development of 
DPN.  It is hypothesized that increased levels of aldose reductase and advanced glycation 
end products (AGEs) are important components in hyperglycemic toxicity within the SC 
[55, 101].  The increase in sorbitol levels can lead to the accumulation of fructose, a 
powerful glycator, and an increase in osmotic stress in neuronal cells [102].  Furthermore, 
the activation of poly (ADP-ribose) polymerase (PARP) by hyperglycemia can deplete 
NAD levels resulting in a dysfunction of glycolitic and mitochondrial respiration 
pathways [103-106].   
The modification of proteins by elevated glucose levels can result in protein 
aggregation resulting in cellular dysfunction.  Since chaperones aid in protein folding and 
are elevated during the unfolded protein response, recent studies have examined the role 
of heat shock proteins (Hsp) in the development of DPN [44].  Hsp 90, the principle 
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coordinator in the chaperone stress response, was examined using KU-32, an Hsp90 
inhibitor.  However, KU-32 is also known to increase levels of Hsp70, an anti-apoptotic 
chaperone.  In vitro experiments using rat embryonic dorsal root ganglions (DRGs) and 
SC-DRG cocultures in 45mM glucose concentrations demonstrated an increase in cell 
death that was prevented by the addition of KU-32.  Interestingly, a disturbance in 
sensory nerve conduction and motor nerve conduction velocities in C57BI/6 
streptozotosin (STZ) induced diabetic mice were also prevented by the addition of KU-
32.   Since it was known that KU-32 was also able to increase Hsp70, a diabetic mouse 
model with the genetic deletion of Hsp70.1 and 70.3 (Hsp70.1/70.3 double KO) was 
generated and, after the development of diabetes, treated with KU-32.  The data showed 
that Hsp 70.1 and 70.3 double KO mice developed DPN that was not prevented by the 
addition of KU-32.  The results indicated that the prevention of DPN by KU-32 was 
dependent on levels of Hsp70 [107].     
Current studies have suggested that hyperglycemia alone is not sufficient to 
induce significant SC death, myelin damage or reduce the total number of myelin 
segments associated with DPN [59, 84, 108].   Gumy et al.,  (2008), observed that SC rat 
cultures exposed to high glucose alone (24 hours) demonstrated  a hindrance of  neurite 
outgrowth, a decline in proliferation and a delay in migration without  the induction of 
cell death.  Cytochrome c release, caspase3 activation and nuclear fragmentation were not 
detected in hyperglycemic SC.  Furthermore, co-culture of SC and axon explants and SCs 
alone cultured on laminin demonstrated a disorganized alignment in hyperglycemic 
conditions with no cellular death.  It is believed that a similar situation occurs when SCs 
separate from the peripheral nerve when high glucose concentrations are encountered in 
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vivo. Thus, this study hypothesized that hyperglycemic changes observed in SCs is an 
additive but not a causative factor in the pathogenesis of DPN [108]. 
Vincent, et al., (2009) suggested that a possible explanation for increased 
resistance of SCs to hyperglycemic conditions may be due to their ability to increase 
cellular antioxidant concentrations, such as catalase, when they encounter an insult.  The 
study found that under hyperglycemic conditions (20mM glucose), SCs were able to 
increase levels of Nrf2, a transcription factor that increases antioxidant gene expression 
in the brain [84].  The capacity of SCs to be resistant to a hyperglycemic environment  
leads to the belief that a second insult, possibly FFAs, will exceed the cell’s survival 
threshold and results in SC cell death.  
 
Peripheral Myelin Protein 22 and Neuropathy 
 
Since SCs are the manufacturers of myelin in the peripheral nervous system, the 
death of these cells can lead to a disruption in myelin production, leading to segmental 
demyelination.  Myelin is comprised of SC plasma membrane which is 70-80% lipid and 
15 -30% protein.  The plasma membrane of one SC is able to wrap around one portion of 
a single axon.  The resulting unmyelinated axonal areas, called nodes of Ranvier, are 
replete with sodium channels that will depolarize the axonal membrane causing an 
electrical impulse to course through the myelinated portions of the axon to the next node 
of Ranvier.  The movement of the impulse from one node of Ranvier to the next is called 
salutatory conduction. Due to the insulating characteristics of myelin, axonal membrane 
depolarization is conducted with far less energy and increased
 
speed when compared to 










































Figure 4. Anatomy and transmission of nerve conduction velocity in the peripheral nerve.  
Schwann cells (SC) will wrap around axons and produce myelin in small sections of the 
peripheral nerve.  Depolarization will take place at the Nodes of Ranvier. The impulse 
generated will coast through the myelinated areas until the next node of Ranvier is 
reached where depolarization will be repeated.  Depolarization occurring from one node 




The increase in conduction velocity is only one of the many functions of myelin. 
Studies have shown that axonal development and regeneration are not efficient and 
cannot be completed in the absence of myelin [110-111].  Recent studies found that 
neuregulin-1 (NRG1), a protein secreted by axons that regulate SC differentiation, 
proliferation, motility, axon ensheathment and myelination, is essential in the 
regenerative process after peripheral nerve injury.  Uninjured NRG1- deficient mice 
showed normal myelin sheaths and undisturbed neuromuscular junctions.   After a sciatic 
nerve crush injury, NRG1-deficient mice demonstrated 1) severe defects in remyelination 
or exhibited no myelin sheath production, 2) slower axonal regeneration process, and 3) a 
malformed neuromuscular junction.  The study suggests that NRG1 is needed in the 
production of myelin after demyelination caused by neuronal injury and, furthermore, 
points to the necessity of myelin sheath in the nerve regeneration process [112].  
Metabolic damage to the peripheral nerves can affect the myelin sheaths first, 
leading to segmental demyelination and axonal damage [113-114].  Nerve biopsies of 
two cats exhibiting diabetic neuropathy demonstrated a disruption and a ballooning of the 
myelin sheaths before axonal damage was observed.  SCs exhibited “reactive, 
degenerative and proliferative changes” in the absence of axonal injury. These findings 
and others suggest that the metabolic disruptions observed in DPN may have a direct 
effect on SCs first before axonal damage is achieved [115-116].    Because myelin is 
initially disrupted, the Peripheral Nerve society has stated that myelinated fiber density 
may be a useful indicator of electrophysiological dysfunctions in the injured nerve [117].   
Myelin is critical for the proper function of the peripheral nerve.  However, in 
order for myelin to work properly, adequate levels of myelin components, such as 
 
28 
proteins, are necessary.  Peripheral myelin protein 22 (PMP22) is one of the most 
important myelin proteins in the peripheral nervous system and has been associated with 
the development in peripheral neuropathies [118]. PMP22 makes up 2-5% of the total 
myelin protein and is incorporated into the membrane of compact myelin.  It has been 
demonstrated that PMP22 protein decreases when myelin is disrupted and increases in 
axonal regeneration [119].  
 
Schwann Cell Model 
 
SCs are in direct contact with the axons and are responsible for many functions in 
the peripheral nerve such as 1) producing of myelin that will sustain the nerve conduction 
velocities of myelinated axons, 2) providing immunological and functional integrity to 
the axons through the blood brain barrier, 3) regulating axonal diameter and 
neurofilament spacing, and 4) most importantly, aiding in nerve regeneration and axonal 
guidance  [120]. Unfortunately, studies have demonstrated that SCs are unable to regulate 
glucose entry into the cell, which makes them more vulnerable to elevated levels of 
glucose.  In addition, SCs tend to be more sensitive to conditions that generate calcium 
overload and ASCOS [121-123] 
 Studies have shown that SC dysfunction, demyelination and axonal atrophy are 
three prominent abnormalities associated with peripheral neuropathies and axon 
degeneration [84-87, 89, 124-126].  Since it has been demonstrated that SCs undergo 
detrimental changes before axonal injury is detected and, furthermore, the wellbeing of 
the SC is required for proper peripheral nerve regeneration, it is critical to examine the 





Currently, the treatment of neuropathy continues to be ineffective.  The primary 
target of DPN and PN treatments only focuses on symptoms.  It is suggested that pain 
medications can only reduce neuropathic pain by 30-50%  but cannot completely 
eliminate it [127].  Medications such as tricyclic antidepressants and anticonvulsants 
continue to be used to treat DPN without the understanding the mode of action.   
Furthermore, these medications do not address the prevention or reduction of neuronal 
injury in the progression of neuropathy [128]. 
Metformin, an oral hypoglycemic agent, has also proven to be ineffective in 
treating DPN.  Presently, clinical studies are investigating the effects of lipid lowering 
therapies on DPN.  The Fremantle diabetes study concluded that lipid-lowering therapy 
may protect against DPN.  It is suggested that SC function, polyol pathway function and 
neuronal blood supply are improved with lipid-lowering therapy; however, the actual 
mechanism continues to be unclear [129-130].   Similarly, it has also been demonstrated 
that pancreatic transplantation can only stabilize neuropathy without offering any 
neuronal recovery [131]. 
 
Rationale and Hypothesis of this Study 
Elevated levels of saturated long chain fatty acids are a major contributor of 
lipotoxic cellular injury.  Obese and type 2 diabetic individuals demonstrate a serious 
derangement in lipid metabolism, which results in elevated free fatty acids (FFAs) 
circulating in the blood. One of the debilitating complications in type 2 diabetes is the 
development of PN.  Hyperglycemia, exhibited by type 2 diabetics, has been greatly 
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examined in the field of PN. However, the mechanism by which PN develops continues 
to be unclear.  In addition, studies are now demonstrating that hyperglycemia alone is not 
sufficient to induce significant myelin damage or damage a sufficient number of myelin 
segments that can lead to peripheral neuropathy [132].  Therefore, the long term goal of 
this study is to better understand the mechanism by which FFAs in combination with 
hyperglycemia injures the SC and results in the development of DPN.  Knowledge of this 
mechanism could lead to the exploration of conventional therapeutic opportunities to 
treat DPN.  Our experimental focus is on the injury of SC by elevated levels of PA, a 
saturated fatty acid which has been demonstrated to be a major contributor of LTx.  
Our hypothesis is that elevated levels of PA will induce LTx in Schwann cells 
cultured in a euglycemic and hyperglycemic environment leading to Schwann cell death.  
These findings can elucidate the possible role of LTx in the development of DPN.    
 
 
Approach of this Dissertation Research 
The specific aims of this study were to 1) examine whether PA induces cell death 
in Schwann cells (SC) cultured in hypoglycemic, euglycemic and hyperglycemic 
conditions, 2) investigate the involvement of the endoplasmic reticulum (ER), 
mitochondria and lysosome in PA-LTx in vitro, and 3) explore the effects of increased 
concentrations of PA on myelin proteins and their possible contribution to the 
development of peripheral neuropathy. 
 PA-LTx was examined by culturing immortalized Schwann cells (iSC) and 
primary SCs (pSC) in different concentrations of glucose.  Cells were cultured for 4 days 
in their respective glucose concentrations to mimic a chronic hyperglycemic environment 
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before being treated with PA.  PA was dissolved in ETOH and complexed with fatty acid 
free Bovine Serum Albumin (BSA) in serum free medium to serve as a buffer for PA. 
Cells were treated with PA: BSA ratio of 1:1(150uM/150uM) and 2:1 (300uM/150uM).   
To examine the apoptotic cell death pathway by PA-LTx, a time course using dual 
parameter flow cytometry for Annexin V-FITC (which binds to early apoptotic cells) and 
7AAD (which detects cells in apoptosis) was performed, in addition to trypan blue, and 
Hoechst staining.  Our  data demonstrated that iSCs as well as pSC cultures exposed to 
elevated levels of PA exhibited a loss in cell viability that was dose and time-dependent.  
This lipotoxic effect was more dramatic in hyperglycemic cultures.   
 The earliest indication of cellular dysfunction was a decrease in Ca
++
 levels in the 
endoplasmic reticulum ([Ca
++
 ] ER) which was detected by the  QuantiChromTM Calcium 
Assay Kit.  The release of Ca
++
 into the cytosol was observed at an earlier time in 
hyperglycemic conditions. This decrease in [Ca
++
]ER was associated with a significant 
change in the expression of ER stress signature genes such as  CHOP, Xbp1 and GRP78. 
The disruptions in ER stress genes were analyzed by Real Time PCR (RTPCR).  
Furthermore, treatment of iSC cultures with the calcium chelator BAPTA-AM resulted in 
an increase in cell viability.  Following the ER stress response, a strong mitochondrial 
membrane depolarization was also observed by flow cytometry using JC-1 dye in which 
an earlier MMD was observed in hyperglycemic conditions.  Using acridine orange 
assays, our data further demonstrates that PA-LTx can trigger lysosomal membrane 
destabilization and release cathepsins that can intensify cellular dysfunction. 
Interestingly, a delay in lysosomal involvement was exhibited in hyperglycemic SCs.  
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 Furthermore, flow cytometry using 2’, 7’-dichlorodihydrofluorescein diacetate (H2DCF-
DA) showed an increase in oxidative stress after PA treatment. A significant amount of 
oxidative stress was observed in hyperglycemic environments before it was detected in 
euglycemic conditions.  Treatment with antioxidant MCI-186 reduced oxidative stress 




The proposed study is important for various reasons.  First, data generated may 
provide insights about the relevance of the lipotoxicity process in terms of its effects to 
supporting cells of the peripheral nervous system.  Most of the studies of lipotoxicity 
have been done in non-neuronal cells, such as hepatocytes, and little is known of 
mechanisms on how the lipotoxic process affects neuron/glial function. Recently, there 
has been an increased interest in the effects of lipids on neurons and glial cells because of 
their potential role in neurodegenerative diseases, such as Alzheimer’s disease [133]. 
Therefore, it is our objective to reveal the possible induction of SC death by FFAs 
and the potential augmentation of cellular injury by hyperglycemia in the development of 
DPN.   This study is of great significance because it will impart insight into the possible 
mechanism of the development of DPN.  In addition, understanding this mechanism will 
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Lipid overload resulting in lipotoxicity is prominent in a number of chronic 
diseases and has been associated with cellular dysfunction and cell death. This study 
characterizes palmitic acid-induced lipotoxicity (PA-LTx) in Schwann cell cultures 
grown in normal and high glucose concentrations. The study shows for the first time that 
Schwann cell (SC) cultures exposed to elevated levels of PA exhibit a dose and time –
dependent  loss in cell viability.  Hoescht and Annexin V/7AAD staining confirmed cell 
death through apoptosis and the lipotoxic effect was more dramatic in SC cultures grown 
under  high glucose conditions. The first indication of cellular dysfunction in treated SC 
cultures was a decrease in Ca
++ 
levels in the endoplasmic reticulum (ER, [Ca
++
 ] ER) 
observed five minutes following the initial challenge with PA. This decrease in [Ca
++
 ]ER 
was followed by a significant increase in the expression of ER stress signature genes 
CHOP, Xbp1 and GRP78. The early ER stress response induced by PA-LTx was 
followed by a strong mitochondrial membrane depolarization.  Flow cytometry using 2’, 
7’-dichlorodihydrofluorescein diacetate (H2DCF-DA) showed an increase in oxidative 
stress within three to six hours after PA treatment. Treatment of cultures undergoing PA-
LTx with the calcium chelator BAPTA-AM and the antioxidant MC1-186 significantly 
reversed the lipotoxic effect by decreasing the generation of ROS and significantly 
increasing cell viability.  We conclude that lipotoxicity in Schwann cells results in 
cellular dysfunction and cell death that involves a robust ER stress response, 






 Normal cellular functions depend on the availability of adequate levels of free 
fatty acids (FFA) that are an important for critical normal metabolic activities [2].  
However, a significant metabolic disarray and cellular dysfunction can occur when 
tissues and cells are chronically exposed to elevated levels of FFAs as observed in 
connection with type 2 diabetes and obesity [11-12, 134-136]. While adipocytes have the 
proper cellular machinery to store and safely utilize high amount of these FFAs, non-
adipose  cells are vulnerable to lipid overload which can induce lipotoxicity and apoptotic 
cell death [5, 22] Lipotoxicity in non-nerve cells is well documented in the literature [39-
40, 137-138].  For instance, pancreatic beta cells exposed to high levels of palmitic acid 
(PA) exhibit a dramatic dysfunction and apoptotic cell death [15-18]. It has been shown 
that lipotoxicity-induced apoptosis and beta cell death in the pancreas precedes 
hyperglycemia suggesting that can be an important factor in the onset of type 2 diabetes 
[19-22]. 
 Nerve cells are exposed to multiple pathologies that can  lead to lipid overload 
and lipotoxicity that can result in lipid peroxidation and lipotoxicity [64, 139-141].  
During ischemia, there is a significant increase in lipid peroxidation in membranes of the 
endoplasmic reticulum (ER), mitochondria and lysosomes  which may contribute to the 
marked dysfunction and cell death observed in this condition [142]. Ceramide, a lipid 
species that forms from fatty acyl CoA and sphingosine, is elevated in the white matter of 
post-mortem brains of patients with Alzheimer’s disease [143-144].  Traumatic injuries in 
the brain and spinal cord result in a significant increase of FFAs that is believed to play a 
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role in the extensive amount of cell death and tissue damage occurring during the 
secondary phase of the condition [145-147].   
 Our laboratory is interested in examining the role and impact of lipotoxicity in 
the nervous system. Previous reports have shown that stearic acid and PA trigger a strong 
apoptotic cell death response in nerve growth factor differentiated pheochromocytoma 
cells (PC12 cells) and cortical cells cultures [35, 64].  This lipotoxic effect was shown to 
be specific for saturated fatty acids such as palmitic (PA) and stearic acid, because 
treatment with oleic nor arachidonic acids at the same concentrations did not trigger a 
lipotoxic response [35]. The lipotoxic cell death process is caspase-independent and 
involves a significant differential expression in  gene expression of fas ligand/receptor 
and members of the Bcl2 family [35].  Caspase-independent cell death can occur through 
significant dysfunction of vital organelles such as the endoplasmic reticulum, lysosomes 
and mitochondria suggesting that calcium and oxidative cellular disruptions may play a 
key cellular role in this process [35, 41, 64]   The aim of this study was to assess whether 
ER stress and ROS production are principal contributors to  the PA-LTx process in 
Schwann cells grown under hyperglycemic and euglycemic conditions. This study shows 
for the first time that Schwann cells (SC) chronically exposed to PA overload exhibit 
dramatic lipotoxicity and apoptotic cell death by a mechanism that require ER stress 
followed by an augmented state of cellular oxidative stress (ASCOS) and mitochondrial 
dysfunction. Further, PA-LTx occurred in a dose and time dependent manner, and is 
significantly stimulated by high glucose. These data is important considering that 
pathological conditions that lead to lipid overload can result in SC dysfunction, 
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demyelination and axon atrophy, three prominent abnormalities associated with 







The Schwann cells used in this study were a generous gift from Dr. Laurel Bolin 
[148].  This “spontaneous immortalized SC clone” (iSC) was shown to express markers 
specific to primary SC such as S100β, p75 
NGFR
 and Vimentin [148-151].  Cells were 
maintained in culture medium prepared from Dulbecco’s modified Eagle’s 
medium/Ham’s F12 (DMEM/F12) 50/50 mix without glutamine (Mediatech, Herndon, 
VA).  This medium contains 17 mM glucose (i.e. the euglycemic condition for this 
study). Ten percent horse serum (Invitrogen, Carlsbad, CA), 2 mM L-glutamine 
(Mediatech), 100 units/ml penicillin and 100 µg/ml streptomycin (Mediatech) were 
supplemented to the media.  iSC cells were incubated at 37
º 
C with 5% CO2 .  Culture 
media was changed every three days. Cells were used at a maximum of 7 passages.   To 
achieve desired hyperglycemic and hypoglycemic state of the culture media, we also 
prepared DMEM beginning with powder DMEM (Mediatech) without glucose, L-
glutamine, phenol red, pyruvate or sodium bicarbonate.  These were added at the 
appropriate concentrations after DMEM was dissolved in sterile deionized water. To 
make hyperglycemic media, 45 mM dextrose (equals to 90 mM glucose) was 
supplemented and no additional glucose was added to make hypoglycemic media. Next, 
DMEM was filtered and mixed with equal volume of Ham’s F12 (contains 10 mM 
glucose) to make final DMEM/F12 (50/50) media with 50 mM glucose (hyperglycemic) 
 
48 
or 5 mM glucose (hypoglycemic) respectively. Further, 10% horse serum, 2 mM L-
glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin were also added.     
 
 
Fatty Acid Treatment 
 
Treatments were done in serum free media.  Serum free media consisted of 
DMEM/F12 (50/50), 2 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml 
streptomycin, and 1X N-2 supplement (Gibco, Invitrogen Corp.). The iSC cells were 
plated in full serum media, placed in the incubator and allowed to attach for 5 hr.  The 
media was removed, washed with Dulbecco’s Phosphate-Buffered Saline (DPBS) and 
transferred to serum free media. After 12 hr in serum free media, cells were treated with 
the selected concentrations of PA complexed with BSA as described previously [35, 64]. 
The PA (Sigma-Aldrich, St. Louis, MO) stock was prepared in 100% ethanol at a 
concentration of 300 mM.  Fatty acid-free BSA (EMD Biosciences, San Diego, CA) was 
used as a buffer to ensure that concentrations of unbound free PA in the media were in 
the 10 nM range during the course of incubation [35]. In brief, serum free medium 
containing 150 µM fatty acid-free BSA was prepared and warmed up to 37
º
C to aid in the 
complete disassociation of PA.  Once media was warm, PA stock was added while 
vortexing to avoid clumping of PA.  Two treatment concentrations were used: 150 µM 
PA (PA:BSA, 1:1) and 300 µM PA (PA:BSA, 2:1).  Treatment media were place in the 
water bath at 37
º









Cell Viability Assays 
 
Trypan Blue Exclusion Assay  
iSC cells were plated in T25 flask at a density of  2.5 x 10
5
 cells/flask. After 
PA/BSA treatment, cells were trypsinized and centrifuged at 700 x g for 5 min and 
resuspended in 500 µl of DPBS with 10% glycerol.  Trypan Blue 0.4% solution (500 µl, 
Sigma-Aldrich) was added immediately before counting cells using an inverted 
microscope. At least 1000 cells were counted for each flask. Percent of blue cells 
(damaged cells) and clear cells (viable cells) in a given field were recorded.  
 
 
Crystal Violet Assay  
 
Briefly, iSC cells were plated in 96 well- tissue culture plates at the density of 1.0 
x 10
4
 cells/well.  Subsequent to 24 or 48 hr treatment of PA, 100 µl/well of 4% 
formaldehyde was added.  Following a 5 min incubation period at room temperature, the 
fixative was removed and cells were washed twice with distilled water.  Afterward, cells 
were post-fixed with 4% formaldehyde for another 30 min.  iSC cells were then washed 
twice with distilled water and allowed to dry completely.  Once dried, 100µl/well of 
crystal violet dye (Accustain®, Sigma-Aldrich) was added and incubated for 30 min at 
room temperature.  Cells were washed with distilled water to remove any unbound stain 
and dried.  The bound crystal violet was then dissolved with 100µl/well of 10% acetic 
acid solution and place in rocker for 10 min at room temperature. The plate was analyzed 
by µQuant (Bio-Tek Instruments, Winooski, VT) using an optical density (O.D.) of 570 







Similar to crystal violet assay, iSC cells were plated in 96 well plates.  After 
treatment, WST-1 (10 µl, Roche Applied Science, Indianapolis, IN) in 100 µl of serum 
free media was added to each well.  The plate was incubated at 37
º
C with 5% CO2   for 2 
hr and O.D. of 450 nm was determined using the µQuant plate reader.  Data was 





Hoechst 33258 dye was used to assess chromatin condensation in iSC cells. The 
dye (10 µg/ml) was added to the cells and incubated for 10 min at 37
º
C with 5% CO2.  
Nuclear morphology of the cells was then photographed using an Olympus fluorescent 
microscope (excitation/emission wavelength of 365/420 nm).  Cells categorized as 
apoptotic demonstrated apoptotic bodies and increased chromatin condensation.  
 
 
Assessment of Apoptosis by Flow Cytometry 
Annexin V (BD Biosciences, San Diego, CA) and 7AAD (eBioscience, San 
Diego, CA) were used to detect apoptotic changes occurring in PA-LTx in iSC cells.  iSC 
cells (1.25 x 10
4
) were plated in a 6 well plate.  After treatment, cells were trypsinized 
and collected.  They were then resuspended in 40 µl of binding buffer with 2 µl Annexin 
V-FITC.  Cells were incubated for 15 min in the dark at room temperature.  After 
incubation, 160 µl of binding buffer and 2 µl of 7AAD were added.  The cells were 
incubated for 5 min and additional 200 µl of binding buffer was added.   Before 
analyzing, cells were filtered through a cell strainer cap that was fitted to a polystyrene 
round bottom flow cytometric tube. Cells were analyzed using the Becton-Dikinson  
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FACSCalibur®  flow cytometer (Becton-Dikinson, San Francisco, CA).  A total of 
100,000 events were measured per sample.  Annexin V was detected in the FL-1 channel 
(530/30nm) while 7AAD was detected in FL-3 channel (650nm).  Data was collected in 
log scale and analyzed using Cell Quest Pro® software and Flow-Jo® software. 
 
 
Analysis of Mitochondrial Membrane Permeabilization 
 
Disruption of the mitochondrial membrane potential was assessed using the 
lipophilic cationic probe 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylben-zimidazol-
carbocyanine iodide (JC-1, MitoScreen kit, BD Biosciences) as described previously 
[64]. Briefly, unfixed cells were washed with PBS and resuspended in 1X JC-1 assay 
buffer supplemented with 10 µg/ml of JC-1. Cells were then incubated for 15 min at 
37
º
C, washed, and resuspended in 1X JC-1 assay buffer for immediate FACSCalibur® 
flow cytometry analysis. JC-1 in healthy cells was aggregated in mitochondria and 
detected in the FL-2 channel while JC-1 in apoptotic cells with depolarized mitochondria 
membrane potential was indicated by a reduced fluorescence in the FL-2 channel. The 
percentage of cells with disrupted mitochondrial membrane potential was calculated 







To measure the [Ca
++
] in ER after addition of PA in iSC cells, the Fluo-4 NW 
Calcium Assay kit (Invitrogen) was used.  Briefly, 1.0 x10
4
 cells were plated in 96 well 
poly-D- lysine coated plates. Cells were treated accordingly.  Afterward, 100 µl of the 





C for 30 min, then at room temperature for another 30 min.  In the last 2 
min of room temperature incubation, Thapsigargin (1µM) or DMSO (vehicle) was added 
to the cells in order to deplete Ca
++ 
from ER. Cells were analyzed using the Envison HTS 
Microplate reader (Perkin-Elmer ® Life and Analytical sciences, Shelton, CT).  





 Chelating by BAPTA-AM 
 
BAPTA-AM (1,2-bis-(o-Aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid 
tetraacetoxymethyl ester, Invitrogen) was used as a  Ca
++
 chelator to reduce intracellular  
Ca
++ 
levels in iSC cells while undergoing PA treatment. BAPTA-AM was dissolved in 
DMSO and co-treatment of 5 µM BAPTA-AM and 300 µM PA was used.  Cell viability 
was assessed by crystal violet after 24 and 48 hr treatment.   
 
 
Inhibition of NMDAR by D-AP5 
 
D-AP5, D-(−)-2-amino-5-phosphonopentanoic acid, (Tocris, Bristol, UK)  was 
used to inhibit NMDA receptors in iSC cells. D-AP5 was dissolved in ddH20 and a co-
treatment of 50µM D-AP5 and 300µM PA was utilize.  Cell viability was analyzed using 





Total RNA was extracted using TRI-Reagent (Molecular Research Center, 
Cincinnati, OH).  RNA quantification was done by measuring O.D. at 260 nm and stored 
at -80
º 
C.  Two-step RT-PCR was performed. First, RNA (0.5~ 1µg) was used to make 
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cDNA using the iScrip cDNA synthesis kit (Bio-Rad, Hercules, CA). Next, real-time 
PCR with Syber Green was conducted using CFX96 Real-Time System (Bio-Rad).  For 
that, CHOP reverse primer 5’-TCC-TCA-TAC-CAG-GCT-TCC-AG-3’ and forward 
primer 5’-CAG-CGA-CAG-AGC-CAA-AAT-AA-3’, GRP78 reverse primer 5’-ATA-
GGG-CTC-TGC-TGG-AGT-CA-3’ and forward primer 5’- CTA-CCC-ACC-TTT-TGC-
CAC-TC-3’, Xbp1 reverse primer 5’-TTT-CTA-TCT-CGC-GCA-GTC-TGT-3’ and 
forward primer 5’-CCC-CCA-AAG-TGC-TAC-TCC-TA-3’ were used. ß-actin was 
selected as a housekeeping gene (reverse primer 5’-GCG GCA GTG GCC ATC TC-3’ 
and forward primer 5’- GGG AAA TCG TGC GTG ACA TT-3’). The relative amount of 
mRNA was calculated using the 2 -∆∆CT formula. 
 
 
Reactive Oxygen Species (ROS) Detection 
 
Detection of oxidative stress was done by staining the iSC cells with 20 µM of 2’, 
7’ dichlorodihydrofluorecein deacetate (H2DCFDA, Invitrogen) for 20 min at 37
º 
C.   
Cells were then detached by trypsinization and washed twice with DPBS. After filtered 
through cell strainer cap, cells were analyzed using a FACSCalibur®  flow cytometer.  A 
total of 10,000 events were measured per sample.  Excitation/Emission wavelengths were 
488 nm and 530/30 nm respectively.  Data was collected in log scale and analyzed using 
Cell Quest Pro® software and Flow-Jo® software. Antioxidant MCI-186 (Biomol 
Research Laboratories, Plymouth Meeting, PA) was used to reduce ROS during PA-LTx. 
MCI-186 was first dissolved in DMSO and warmed up to 37
º 
C to ensure the complete 
disassociation.  MCI-186 stock solution (or DMSO as a control) was then diluted into the 





Western procedures have been described elsewhere [35, 152]. Protein extract 
from iSC were separate on a SDS-PAGE gel and electrophoretically transferred to a 
nitrocellulose membrane. After transfer, the membranes were blocking with 5% milk in 
Tris-buffered saline (TTBS) with 0.05% Tween 20, PH 7.4 at room temperature for 1 hr. 
The membranes were then incubated with specific antibodies against different protein, 
GRP78 and CHOP/Ddit3 (Abcam) in TTBPS containing 0.05% Tween 20 at 4ᵒC 
overnight. Subsequently the membranes were washed three times with TTBS and 
incubated with HRP-anti mouse or HRP-anti rabbit (GE Healthcare Bioscience) for 1 hr 
at room temperature, followed by three washes with TTBS. The signal was then detected 
by ECL-plus (GE Healthcare Bioscience). Quantitative analysis of the protein was 
performed by densitometric scanning of the autoradiographs by employing the using 
ChemiImager
™




All the experiments were repeated independently at least three times. Values 
represent means ± SE.  Statistical comparisons were made using Student t test. 




Cell Viability and Lipotoxicity in Immortalized Schwann Cells (iSC) 
Cultures in Different Glucose Concentrations 
 
Chronic elevated plasma levels of saturated FFA have been reported to cause 
dysfunction and injury in affected tissues and cells [12, 153-156].  Previous reports from 
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our laboratory have shown that PA (PA:BSA 2:1, see Experimental Procedure) induces 
lipotoxicity and cell death in nerve growth factor differentiated PC12 cells and rat 
cortical cells [35, 41, 64]. This experimental paradigm exposed cells to a 10 nM range of 
unbound FFA concentration which parallel to levels found in conditions such as diabetes 
and ischemic injury [64, 157-159]. 
Our initial experiments determined the changes in cell viability under three 
different conditions: 1) hypoglycemic (5mM glucose), 2) euglycemic (17mM glucose) 
and 3) hyperglycemic (50 mM glucose) [160]. In all of our studies, cells were cultured in 
the indicated glucose concentrations for 4 days before the exposure to PA. Our results 
show that glucose level alone did not affect viability of iSC cells at any of the 



























Figure 1: Cell viability under varied glucose and PA concentrations. iSC cells were 
cultured in medium containing 5, 17 or 50 mM glucose for 4 days + 24H (A) and 4 days 
+ 48H (B) before the addition of PA. Cell viability was assessed by trypan blue assay 
after 24 and 48 hr. Statistical analysis was performed using student’s t-test.. *p< 0.05, 





To explore any potential synergistic detrimental effects of FFA and glucose, we 
performed a series of experiments using trypan blue assays to assess viability of iSC after 
exposure to PA at a dose of 1:1 or 2:1 together with these three non-damaging glucose 
concentrations. Figure 1C and 1D shows that under each of these glucose concentrations, 
PA caused a dose- and time-dependent decrease in cell viability.  Cell loss observed in 
cell cultures exposed to PA under hypoglycemic (5 mM glucose) and euglycemic (17 
mM glucose) were similar, however the dose and time-dependent increase in cell death 

















Figure 1: Cell viability under varied glucose and PA concentrations. iSC cells were 
cultured in medium containing 5, 17 or 50 mM glucose for 4 days before the addition of 
PA. After 4 days of pre-conditioning under varied glucose concentrations, PA:BSA (1:1 
or 2:1) was added to the cells at 24H (C) and 48H (D). Cell viability was assessed by 
trypan blue assay after 24 and 48 hr. Statistical analysis was performed using student’s t-




Cell cultures exposed to PA for 24 hr under hyperglycemic condition showed a 
24.3 ± 4.9 % and 60.6 ±19.0 % induction of cell death at PA:BSA 1:1 and 2:1 treatments 
respectively. At 48 hr, hyperglycemic conditions showed dramatically increased cell 
death in PA:BSA 1:1 and 2:1 treatments,  up to 32.7 ± 12.2 % and  83.9± 4.0 %  
respectively (Figure 1D).  
 
 
iSC Cells Undergo Apoptosis During PA-LTx 
 
As shown by Hoescht staining in Figure 2,  numerous cells in the PA: BSA 1:1 
and PA: BSA 2:1 panels exhibit nucleus condensation and apoptotic bodies while those 
in untreated cultures show normally dispersed chromatin and intact nuclear membranes. 
The next series of experiments further quantified this apoptotic process by taking 
advantage of established flow cytometric methods using Annexin V FITC and 7 AAD to 


























Figure 2: PA-LTx induced apoptotic features in iSC cells. To determine nuclear 
morphology, Hoescht staining was performed after 48 hr PA treatment.  Nuclear 
condensation is indicated with white arrows. Representative micrographs of five 
independent experiments are shown. 
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Figure 3A shows that there is a significant increase in the number of apoptotic 
iSC cells at 6 hr following exposure to PA in euglycemic cultures (8.69% early apoptotic, 
5.38% late apoptotic cells) and the proportion of apoptotic cells continued to rise up until 
48 hr of PA treatment (26.60% early apoptotic, 21.95 % late apoptotic cells). In contrast 
to the euglycemic conditions, cultures grown in hyperglycemic conditions exhibited an 
earlier and more pronounced increase in cell death. Cell death in the hyperglycemic 
conditions occurred as early as 3 hr (3.40% early apoptotic, 4.40% late apoptotic cells) 
and continued to increase reaching a peak at 48 hr (41.98% early apoptotic, 24.80% late 































Figure 3: Time-dependent induction of apoptosis by PA-LTx. Time course experiments 
of Annexin V and 7AAD flow cytometric assay of apoptosis were performed on PA 
treated iSC cells cultured in (A) euglycemic and (B) hyperglycemic media. Early 
apoptotic translocation of phosphotidyl cistein to the outer cell membrane renders the cell 
Annexin V+, while late apoptosis is detected by entry and retention of 7AAD in the 
nucleus. The percentages of cells that are Annexin V-/7AAD- (non apoptotic). Annexin 
V +/7AAD- (early stage apoptosis) and Annexin V+/7AAD+ (late stage apoptosis) are 
graphed. Statistical analysis was performed using student’s t-test. *p< 0.05, **p<0.005, 
N=4 
67 
Early Mediators of PA-LTx in iSC Cells: 
Potential Role of Intracellular Calcium 
 
In the nervous system, neurons and associated supportive cells like Schwann cells 
are vulnerable to conditions that generate calcium overload and ROS as is evident in 
ischemic and traumatic injuries [121-123]. For example, FFA overload has been 
associated with significant ER and mitochondrial dysfunction which may result in Ca
++
 
release and potential toxicity and cell death [24, 40, 64, 161].  The first series of 
experiments examined the potential role of calcium overload by examining releasable 
[Ca
++
] in the ER, the cellular organelle that is most responsible for controlling free Ca
++ 
concentrations in the cytosol. Cell cultures were exposed to 2:1 PA: BSA and Ca
++
 levels 
in the ER ([Ca
++
]ER) were analyzed at 5 min, 15 min, 30 min and 3, 6, 12 hr. Figure 4A 
shows that PA-LTx reduced [Ca
++
]ER  in a time dependent manner in both 17 and 50 mM 
glucose conditions, suggesting that PA was able to impair the capacity of the ER to 
sequester Ca
++
.  In euglycemic cultures, a significant decrease of [Ca
++
]ER was present at 
30 min after PA treatment, while in hyperglycemic treatment, a significant reduction in 
[Ca
++
]ER was observed as early as 15 min after PA treatment and the [Ca
++
]ER  was 
reduced to approximately 25% by 12 hr (Figure 4A). The limit in the capacity of the ER 
to store Ca
++
 imposed by PA-LTx results in an increase of free Ca
++
 in the cytoplasm 
which could lead to cellular toxicity. To test this hypothesis we used a well established 
Ca
++
 chelator, BAPTA-AM, to assess whether we could reduce the lipotoxic injury. 
Figure 4B and 4C shows that BAPTA-AM, as expected, reversed the loss of cell viability 
triggered by PA-LTx in both glucose concentrations and was able to reverse the LTx 
effect at both 24 and 48 hr (Figure 4B, C). These data suggest that PA-LTx in iSC cells 





; resulting in levels of cytosolic Ca
++
 that can cause cell injury.  It is 
important to note that elevated levels of glucose alone did not significantly affect 
[Ca
++




















Figure 4:  Ca
++
 concentration in the ER is reduced with PA treatment. (A) The iSC cells 
were cultured in 17 mM or 50 mM glucose and treated with PA:BSA 2:1.  [Ca
++
]ER, 
reference to control level, was determined at 5, 15, 30 min and 3, 6, 12 hr after treatment. 
(B)(C) Cells were treated with PA:BSA 2:1 in the presence or absence of   BAPTA-AM 
(5µM) or D-AP5 (50µM) for 24 and 48 hr.  Assessment of cell viability was performed 
by crystal violet assays. Statistical analysis was performed using student’s t-test..*p< 





To assess the potential sources of the elevated levels of intracellular Ca
++  
observed under PA-LTx conditions it was important to also examine the possible 
contribution of influx of Ca
++
 from the extracellular space.  A co-treatment of an 
NMDAR inhibitor, D-AP5 (50µM) with PA (2:1) was performed in order to test for the 
contribution of NMDA receptors.  Our data demonstrated that D-AP5 was able to 
significantly increase cell viability in euglycemic and hyperglycemic iSC at 24hr only.  
However, no increase in cell viability was observed at 48hr (Figure 4B, C).  
 
As shown above, the effect of PA-LTx on ER dysfunction and Ca
++
 released into 
the cytosol is the earliest event of PA-LTx that was observed in iSC cells.  To further 
examine the effects of PA-LTx on the ER, the mRNA expression of well-established ER 
stress response proteins such as CHOP, GRP78 and Xbp1 were examined [162-164].  
CHOP, also known as Ddit3, is a transcription factor that mediates the ER stress-induced 
apoptotic pathways. The mechanism by which CHOP induces apoptosis remains unclear 
although it has been implicated in the inhibition of  the transcription of anti-apoptotic 
Bcl-2 proteins [163-164].  ER stress genes were examined using quantitative real time 
PCR at 0, 3, 6, 12, 24, and 48 hr following exposure to PA:BSA 2:1. We found that PA-
LTx triggers a robust up-regulation of CHOP mRNA at 6, 12,  and 24 hr in euglycemic 
and hyperglycemic conditions (Figure 5A and 5B).  Spliced Xbp1 is a transcriptional 
activator that induces genes that encode for ER-associated degradation, chaperones, and 
lipid synthesis [45, 163].  PA-LTx induced a modest increase in mRNA levels of Xbp1 at 
6 hr and reached a peak at 24 hr in euglycemic cells. However, Xbp1 was only 
significantly up-regulated at 24 and 48hr in hyperglycemic cells (Figure 5A and 5B).  
Grp78 is a 78 kDa glucose regulated protein that resides in the ER and tends to be up-
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regulated when the cell is exposed to environmental stressors [165-167].  Interestingly, 
mRNA levels of GRP78 were significantly down-regulated at 24 and 48 hr in euglycemic 
and had a maximum 5-fold up-regulation in hyperglycemic conditions at 48 hr. (Figure 















Figure 5: ER stress genes are regulated with PA treatment. RT-PCR was performed to 
measure mRNA levels of ER stress genes CHOP, Xbp1, and Grp78 in iSC cells at 0 
(CTL), 3, 6, 12, 24 and 48 hr after adding PA:BSA 2:1 in euglycemic (A) and 
hyperglycemic conditions (B). In addition, ER stress genes where also evaluated after a 
co-treatment of PA and BAPTA-AM in both euglycemic (C) and hyperglycemic (D) 






Furthermore, we also examined the effect of PA on the protein levels of these ER 
stress genes at 0, 6, 12, 24, and 48 hr by using Western blots. We found that PA-LTx 
triggers a robust up-regulation of CHOP protein levels at 12 hrs  which returned to 
normal levels at 24 and 48 hr in euglycemic and hyperglycemic culture conditions 
(Figure 6A and 6B).  In addition, the proteins levels of GRP78 were significantly up-
regulated at 12 hr and returned to control expression at 24 hrs and 48 hr in the 
euglycemic condition (Figure 6C).  However, in hyperglycemic condition we observed a 
significant increased in the protein levels of GRP78 at 24 hrs that remained elevated at 48 
hrs (latest time point measured, Figure 6D). We were not able to performed Western 




















Figure 6: ER stress proteins are altered after PA treatment. Cells lysates of iSC from 
euglycemic and hyperglycemic condition at 0 (CTL),6, 12, 24 and 48 hr after adding 
PA:BSA 2:1. were prepared and subjected to Western blot analysis using specific 
antibodies against CHOP (A,B top) and GRP78(C,D top). The proteins were quantified 
by densitometric scanning (A–D, bottom). Statistical analysis was performed using 





ER stress genes were also examined in the presence of BAPTA-AM. In both 
euglycemic and hyperglycemic conditions, BAPTA-AM stabilized GRP78 mRNA and 
maintained its level similar to control through 48 hr after PA treatment (Figure 7A  and 
7B). For XBP1 mRNA levels, a 50% up-regulation of was observed in euglycemic cells 
at 12, 24, 48 hr and a 20% increase showed at 12 hr in hyperglycemic cells during co-
treatment situation (Figure 7A and 7B). PA in the presence of BAPTA-AM still produced 
a significant up-regulation of CHOP mRNA in iSC cells cultured in euglycemic 
environment, however it was not comparable to the levels found with PA treated alone 
(Figure 7A and 7B).  In hyperglycemic conditions, a significant up-regulation of CHOP 

















Figure 7: ER stress genes are regulated with PA treatment. RT-PCR was performed to 
measure mRNA levels of ER stress genes CHOP, Xbp1, and Grp78 in iSC cells at 0 
(CTL), 3, 6, 12, 24 and 48 hr after adding after a co-treatment of PA/BSA 2:1 and 
BAPTA-AM in both euglycemic (C) and hyperglycemic (D).  Statistical analysis was 





Early Mediators of PA-LTx in iSC Cultures: 
Potential Role of Reactive Oxygen Species 
  
We assessed the generation of ROS using 2’, 7’ dichlorodihydrofluorecein 
diacetate (H2DCFDA) and flow cytometry. Flow cytometry analysis was performed at 0, 
3, 6, 12, 24, and 48 hr following exposure to PA.  In agreement with our earlier 
experiments (see figure 1), hyperglycemic conditions in our cell model did not elicit an 
increase in ROS levels (Figure7A). However, the addition of PA:BSA 2:1 induced a 
significant increase of ROS as early as 3hr, followed by further increases at 6, 12, 24, and 
48 hr under  17 mM glucose condition (Figure 8B). With a lower dose of PA (PA:BSA 
1:1), the ROS levels were shown to significantly increase at 12, 24 and 48 hr only (Figure 
8B). In hyperglycemic system, this increase in ROS was observed as early as 3 hr after 
PA exposure and continued to elevate up to 48 hr (Figure 8C).  The magnitude of the 

















Figure 8: ROS analysis using H2DCFDA flow cytometry. iSC cells were cultured in 
hypoglycemic (5 mM glucose), euglycemic (17 mM glucose), and hyperglycemic (50 
mM glucose) media for at least 4 days before analyzing ROS levels by H2DCFDA assay. 
The increase in fluorescence is indicative of an increase in ROS within the cell.  Cells 
treated with 300 µM of H2O2 for 15 min were used as a positive control. (A) 
Representative flow cytometry graphs of iSC cells cultured in different concentrations of 
glucose. No increase in ROS was observed. ROS analysis was performed on iSC cells 
treated with PA:BSA 1:1 and 2:1 in (B) 17 mM glucose and (C) 50 mM glucose 
conditions. Flow cytometry data was quantified using Cell Quest Pro® and Flow-Jo® 






Next, we evaluated the physiological relevance of this ROS elevation by treating 
the culture with MCI-186, a well characterized free radical scavenger [168]. Our data 
show that control euglycemic cell cultures treated with 0.1 mM of MCI-186 exhibited a 
38% reduction in the ROS levels with approximately 93% of the cells viable  at 24 hr 
(Figure 9A and 9C). Subsequently, co-treatment of PA and MCI-186 in euglycemic cell 
cultures  resulted in a 46%  reduction in ROS as compared to PA treatment alone (Figure 
9A). Similarly, the addition of 1 mM MCI-186 to cultures grown under hyperglycemic 
conditions reduced ROS levels by 16% in control and by 47% in PA-treated cells at 24 hr 
(Figure 9B). MCI-186 was found to be toxic in both euglycemic and hyperglycemic 
cultures at 48 hr (data not shown). To examine the effects of this reduction in ROS on 
viability of PA-treated iSC cells, crystal violet viability assays were performed. Figure 
8C shows that iSC cell viability was increased by 20% in PA-LTx cells co-treated with 
0.1mM of MCI-186 under euglycemic conditions (Figure 9C) and completely restored to 
normal levels when 1 mM of MC-186 was added to cells grown in  hyperglycemic 
conditions (Figure 9D). 
Given that BAPTA-AM increased cell viability at 24 and 48hr after PA treatment, 
it was of interest to also evaluate levels of ROS.  Our data demonstrates  that co-
treatment of 5µM BAPTA-AM with 300µM PA was able to significantly decrease ROS 





















Figure 9: MCI-186 and BAPTA-AM reduce ROS levels and increases cell viability in 
PA-LTx iSC cells. The iSC cells were cultured in 17 mM glucose (A, C, E) or 50 mM 
glucose (B,D, F) concentrations and treated with PA:BSA 2:1 (PA) in the presence or 
absence of 100 µM or 1 mM MCI-186 or 5µM BAPTA-AM.  ROS analysis using 
H2DCFDA flow cytometry (A, B) and Crystal violet assay for cell viability (C, D) were 
performed at 24 hr. Cells cultured in euglycemic (E) and hyperglycemic (F) conditions 
were co-treated with BAPTA-AM  for 24 and 48H and analyzed for ROS levels. 





The significant generation of ROS observed after exposure to PA suggests a 
potential increase in mitochondrial permeability and dysfunction. We performed a series 
of flow cytometry experiments using JC-1 to evaluate mitochondrial function. Cell 
cultures were treated with PA:BSA 2:1 and analyzed by JC-1 flow cytometry at 30 min, 
1, 3, 6 and 12 hr after the initial exposure to PA. Figure 10A and 10C show that cells 
grown in euglycemic conditions exhibit significant mitochondria membrane 
depolarization at 6 hr and reached a peak at 12 hr after the initial exposure to PA (Figures 
10A and 10C). Interestingly, cells grown under hyperglycemic conditions show this 
dysfunction as early as one hour after exposure to PA:BSA 2:1 treatment (Figure 10B and 
10D). Hyperglycemia alone did not result in significant mitochondrial depolarization in 























Figure 10: PA-LTx induces mitochondrial depolarization in iSC cells. Mitochondrial 
membrane depolarization was examined by flow cytometric analysis using JC-1 
fluorescent dye. Representative flow cytometric plots of control (CTL) and 12 hr 
PA:BSA 2:1 treatment (12H PA) under (A) 17 mM glucose condition and (B) 50 mM 
glucose condition are shown. R1 quadrant indicates cells with intact mitochondria while 
R2 quadrant represents cells with depolarized mitochondria, i.e. apoptotic cells. 
Quantitative analysis of JC-1 data using Flow JO® software is shown in (C) 17 mM 
glucose condition and (D) 50 mM glucose condition. Statistical analysis was performed 






The present study shows for the first time that exposure to high levels of PA 
results in a strong lipotoxic process that result in apoptotic cell death and is mediated 
though ER stress, ROS generation and mitochondria depolarization. This lipotoxic insult 
increases when cells are cultured under high glucose conditions. Interestingly, the 
calcium chelator BAPTA-AM and free radical scavenger MC1-186 are powerful 
inhibitors of PA-LTx and cell death. Our findings also show that ER stress precedes 
mitochondrial dysfunction and ROS generation after exposure to PA.  
Previous studies have examined the role of high glucose in inducing Schwann cell 
(SC) dysfunction and elucidated its potential role in the development of peripheral 
neuropathy (PN), a common type 2 diabetes morbidity [120, 160] [132].  However, 
because of controversies as to whether hyperglycemia is the primary upstream factor 
responsible of SC dysfunction in PN, another contributor, dyslipidemia, is attracting 
further attention [84, 87, 125-126].  Type 2 diabetes is characterized by a serious 
dysregulation in lipid metabolism resulting in chronic elevated levels of FFA in the 
plasma [12, 136, 153-155].  Thus, it is important to assess the pathological implications 
of hyperglycemia in combination with high levels of FFA in SC viability.  This report 
shows that chronic hyperglycemia alone does not induce iSC  cell death but its presence 
strongly magnified the effects of lipotoxic injury. This is consistent with observations 
that cultures treated with high glucose alone retard neurite outgrowth, slows down 
proliferation and delays migration without inducing cell death in isolated neonatal SC 
cultures [108].  PA-LTx has also been shown to be enhanced by high glucose in 
pancreatic β-cell cell death [169]. The failure of hyperglycemia to induce death of iSC 
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may be due to the activation of cellular pro-survival pathways known to be present when 
cells are exposed to low stress insults. This induced protective status includes the 
generation of anti-apoptotic pro-survival proteins that counteract pro-apoptotic pathways 
stimulated by the low threshold stimuli. The exposure to an additional insult such as lipid 
overload may result in an override of the cell defensive response and result in cell death 
and apoptosis [170-172].  
Long chain saturated free fatty acids (LCSFFA) like stearic acid and PA are 
strong inducers of lipotoxicity and cell death in neurons and other cells [35, 41, 64]. Cell 
membranes containing phospholipids enriched with LCSFFA exhibit lower fluidity [24]. 
These LCSFFA may accumulate in membrane lipid rafts, alter the lipid environment and 
affect important functions of key receptors and other membrane proteins [173-176].  
These LCSFFA also undergo esterification with less efficiency as a result of possible low 
efficiency of the enzymes involved  [5, 25, 30, 156].  Furthermore, these LCFFA 
accumulate in the cell and form diaglycerides and ceramide, which may contribute to the 
cellular dysfunction observed [26, 28-29].  Ceramide is a byproduct produced by 
saturated fatty acids and is a key mediator of cytotoxicity and apoptosis  [177-179].  This 
may be one of the apoptotic pathways that are involved in the PA-induced cell death 
demonstrated in numerous studies using non-nerve cells and in the present study [169, 
180-181].  
 Our data show that PA-LTx in the presence of high glucose results in an early 




into the cytosol from the ER.  The data points to the ER 
as the earliest organelles to be affected by the lipid overload. Studies have shown that 





 is important for the generation of ATP and Ca
++
 sensing 
chaperones and binding proteins are equally important in regulating free cytosolic Ca
++
 
concentrations [183-185]. The data is consistent with a model in which PA initially 
injures the ER membranes, resulting in the release of Ca
++
 into the cytosol and 
overloading the mitochondrial matrix. Although not measured in detail in the present 
study, these series of events would lead to the translocation of AIF and EndoG to the 
nucleus, thus inducing chromatin condensation and DNA fragmentation [186]. Moreover, 
injury to the mitochondria induces the release of cytrochrome c into the cytosol, which 
may contribute to the formation of the apoptosome (cyto-c +Apaf-1 + caspase 9) [61, 
187-188].  
Previous work from our laboratory demonstrated that inhibition of caspase 
activation did not block the lipotoxic process but the present study found that reducing 
excessive cytosolic Ca
++ 
levels using BAPTA-AM inhibited the cell death process.  
Furthermore, our data demonstrates that BAPTA-AM is able to reduce ROS level in both 
euglycemic and hyperglycemic iSC at 24 and 48hr.  Previous studies in the literature 
have shown that buffering calcium with agents such as BAPTA-AM prevented the 
induction of apoptosis in different cellular models by preventing mitochondrial 
membrane depolarization [188-191]. Deniaud et al (2008) et al examined the inner 
mitochondrial membrane permeabilization of HeLa cells and found that after 24 hr 
treatment with ER-stress inducers, such as thapsigargin and tunicamycin, inner 
mitochondrial membrane permeabilization was reduced by BAPTA-AM.  [191]. This 
effect of BAPTA-AM was highly significant even though this drug has a modest effect 
on ROS levels in control cells in control group  [192-193].    
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Besides BAPTA-AM, another factor that can increase cell viability is the 
inhibition of NMDA receptors [194-196].  A study by Yu et al., (2002) found that 
activation of NMDA receptors are needed in order to induce the translocation of AIF 
from the mitochondria to the nucleus, thus leading to apoptosis.  In our hands, inhibiting 
NMDA receptors with D-AP5 increased cell viability at 24hr in both euglycemic and 
hyperglycemic conditions. We speculate that by inhibiting the NMDA receptors, 
translocation of AIF to the nucleus may have been prevented and future experiments will 
address this question. The inability of D-AP5 to increase cell viability at 48hr may be 
explained by the overall severity of cellular injury that drives the cell towards cellular 
death regardless of the inhibition of these receptors.  




ER by PA not only affects normal 
mitochondrial function but also alters the expression of ER stress genes and proteins such 
as CHOP, Xbp1, and GRP78. In euglycemic conditions, PA-LTx triggers the up-
regulation of Xbp1 and CHOP mRNA levels, simultaneously, before significant cell 
death was observed. It was also observed that protein levels of CHOP were increased at 
12hr.  The pattern of gene regulation observed in cells undergoing PA-LTx suggests that 
SC increases the expression of genes that encode for the ER stress response, such as 
chaperones, and transcription factors. These in turn function to decrease the load on the 
ER, therefore promoting cell survival [162-163, 197-198].  In conjunction, these cells 
also promote cell death through up-regulation of CHOP, which down-regulates Bcl-2 
expression, depletes cellular levels of glutathione, translocates BAX from the cytosol to 
the mitochondria, and induces TRB3, an AKT inhibitor that plays a role in ER stress-
induced cell death [163-164, 199].  In addition, the unfolding protein response can 
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activate IRE-1, a transmembrane ER stress sensor, that will engage  TNF receptor-
associated factor 2 (TRAF2) which can  mobilize apoptosis signal-regulating kinase 
(ASK1) resulting in the activation of  c-Jun amino terminal kinase (JNK), a powerful pro-
apoptotic kinase that interacts with  Bcl-2 family proteins [52, 200-202].  Hence, there is 
a period of time where the cell promotes cell survival and cell death simultaneously [203-
204]. Ultimately, as time progresses, one pathway will dominate and govern the fate of 
the cell.  In this manner, PA treated cells will begin to express significantly higher 
mRNA levels of CHOP, in which  Xbp-1 can no longer exert its influence, resulting in 
cellular death.    
An interesting finding was the up-regulation of GRP78 mRNA and protein 
expression in the hyperglycemic state at 24 and 48 hr after PA treatment since up-
regulation of GRP78 is frequently correlated with cell survival [205-206].   Elevation of 
GRP78 expression has also been observed at times when cells are undergoing apoptosis 
[39, 201, 207].  In the spontaneous hypertensive rat model, cardiomyocytes that suffered 
from prolonged hypertension (32 weeks) demonstrated an increase in apoptotic cells and 
expression of significant levels of GRP78, caspase 3 and caspase 12 [208].   
Treatment of iSC cells with BAPTA-AM resulted in the stabilization of mRNA 
levels of pro-survival genes such as GRP78, upregulation of  XBP1 in a euglycemic and 
hyperglycemic conditions.  The decrease in  pro-apoptotic ER stress genes such as CHOP 
was observed in both euglycemic and hyperglycemic conditions.  Thus, reducing the 
stress on the ER by BAPTA-AM, may assist the cell in its attempt to survive by 
promoting anti-apoptotic pathways.      
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The mechanisms by which hyperglycemia potentiates PA injury has not been 
studied in SC. Cell culture studies using beta cells have found that PA increases nitric 
oxide (NO) while high glucose increases levels of superoxide (O2
-
).  However, when the 
cells are exposed to both insults the production of both radicals can lead to the production 
of peroxynitrite (OOON
-
), a powerful free radical known to cause DNA damage and 
apoptosis [169].  Hyperglycemia can also activate PARP which can deplete NAD levels 
and lead to dysfunction of glycolitic and mitochondrial respiration pathways in diabetic 
neuropathy [103-106].    
Our findings indicate that the ER response is the earliest event that follows PA-
LTx. The ER response results in Ca
++
 to be released into the cytosol, affecting the 
mitochondria and leading to mitochondrial membrane depolarization. Consequently, 
mitochondrial dysfunction will result in an increase in levels of ROS and cellular 
metabolic derangements. Moreover, pro-apoptotic and anti-apoptotic pathways will be 
activated simultaneously. As the injury continues, a full ASCOS condition will be in 
place affecting proteins, lipids, and DNA. Further, when high glucose levels are 
incorporated, other factors such as a decrease in anti-oxidant molecules, disruption of 
metabolic activities, including glycolysis and respiratory pathways, and possibly the 
activation of inflammatory mediators can dramatically augment the injury caused by PA.    
Increasing number of studies are linking ER stress to a decrease in myelin production in 
the nervous system [44, 209].  The data is consistent with these studies and agrees with 
these published results and further show that the combination of hyperglycemia and 
palmitic acid overload can cause SC dysfunction and SC death. We propose that similar 
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mechanism maybe happening in vivo that may result in SC dysfunction, cell death, focal 
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Schwann cells (SC) cultured in euglycemic and hyperglycemic conditions 
undergo lipotoxicity (LTx) when treated with elevated levels of PA.  The purpose of this 
study is to elucidate the mechanisms of palmitic acid lipotoxicity (PA-LTx) in primary 
SCs and further uncover the influence of hyperglycemia during the lipotoxic response.  
Our study demonstrated that primary Schwann cells (pSC) exposed to elevated levels of 
PA exhibit a loss in cell viability in a dose and time-dependent manner.  Crystal violet 
assays demonstrated that elevated levels of glucose alone did not result in a significant 
decrease in cell viability in pSCs, however a significant decrease in cell viability was 
exhibited after PA exposure.  Hoescht and Annexin V/7AAD staining demonstrated an 
apoptotic cell death in euglycemic and hyperglycemic pSC treated with PA.  An early 
decrease in Ca
++
 levels in the endoplasmic reticulum (ER, [Ca++ ]ER) was also observed 
in euglycemic and hyperglycemic pSCs undergoing PA-LTx.  In euglycemic pSC treated 
with PA, flow cytometric experiments using acridine orange (AO) demonstrated 
lysosomal membrane destabilization (LMD) that preceded mitochondrial membrane 
depolarization (MMD). In addition, colometric assays demonstrated that PA-LTx was 
able to induce the activation of caspase 3/7 after a 3 hour exposure.  Interestingly, pSCs 
cultured in a hyperglycemic condition demonstrated MMD, and caspase 3/7 activation 
that was followed by LMD. As a result, it is suggested that hyperglycemia may be able to 
delay the involvement of lysosomes in PA-LTx, and increase the intensity to the damage 






An interruption in homeostatic levels of free fatty acids (FFAs) has been 
implicated in many disorders. Adequate levels of FFAs are needed to ensure proper 
cellular functions  but elevated lipid levels can cause havoc to the surrounding tissues and 
cells, leading to debilitating complications, such as those demonstrated by individuals 
with type 2 diabetes [95].  Lipotoxicity (LTx) is the pathological response of cells to 
elevated and toxic levels of FFAs.  It has been shown that LTx can lead to cellular 
dysfunction in many cell types, such as cardiomyocytes, pancreatic beta cells and, 
neurons [41, 53, 210].   
Our lab and others have shown that saturated fatty acids, such as palmitic (PA) 
and stearic acid, can induce LTx that can lead to cellular death [35, 53, 211].  However, 
the mechanisms involving LTx continue to be unclear.  Recent studies in LTx have 
revealed the involvement of organelles such as the endoplasmic reticulum (ER), 
mitochondria and lysosomes [41, 53, 212-213].  A study conducted by Li, Z.Z. et al., 
(2008) revealed that treatment with 200-500µM of PA induced lysosomal membrane 
destabilization (LMD), mitochondrial dysfunction and cell death in two hepatocyte cell 
lines (HepG2 and McNtcp.24) [39].  Similarly, mice fed a high fat diet demonstrated a 
derangement in lipid levels leading to an increase in lipid oxidation and DRG injury, thus 
contributing to the development of diabetic peripheral neuropathy [84]. 
Previous work from our laboratory demonstrated that elevated levels of PA 
resulted in mitochondrial membrane depolarization (MMD), oxidative stress (ROS), and 
LMD in PC12 cells and cortical cells [35, 41].   In addition, in an immortalized Schwann 





 into the cytosol, followed by MMD and ROS production. This study also 
demonstrated that the preconditioning of iSC in a hyperglycemic environment 
dramatically augmented PA cellular injury [213].   
 The aim of this study is to further elucidate the mechanisms of LTx in primary 
SCs (pSC) and to further examine the impact of hyperglycemia in the lipotoxic response.  
Our data show that lipotoxicity induces an early reduction of Ca
++
 stores from the ER 
([Ca
++
] ER), followed by lysosomal membrane destabilization (LMD), mitochondrial 
membrane depolarization (MMD) and an increase in oxidative stress (ROS) in 
euglycemic (5mM) pSC exposed to PA:BSA 2:1 (300µM: 150µM).  Interestingly, pSC 
cultured in hyperglycemic (17mM) conditions demonstrated a robust and earlier 
depletion of [Ca
++
]ER stores, followed by MMD, an increase in ROS levels, and the delay 
in the induction of LMD.  As a result, it is suggested that an alternate pathway in PA-LTx 
is activated when pSC are cultured in hyperglycemic conditions.   
It is of importance to understand the mechanism and the ramifications of LTx, 
considering that SC injury is frequently observed in individuals suffering from peripheral 







Primary Schwann cells (pSC) and Schwann cell medium (SCM) used in this study 
were purchased from Science Cell Research Laboratories™ (Carlsbad, CA).  Cell 
medium consisted of basal medium with a final concentration of 5.5 mM glucose (i.e. the 
euglycemic condition for this study).  SCM was supplemented with 1% Schwann cell 
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growth supplement (SCGS), 5% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin which were also provided by the company. 
pSC cells were incubated at 37
º 
C with 5% CO2.  Culture media was changed 
every three days.   To achieve desired hyperglycemic states (17mM), 11.5mM dextrose 
(equals to 17 mM final concentration) was added to the SCM and filtered before the 
addition of FBS, SCGs, and penicillin/streptomycin.   
 
 
Fatty Acid Treatment 
 
Treatments were done in serum free media conditions.  Serum free media 
consisted of SCM, 1% SCGS, and 1% penicillin/streptomycin (ScienceCell Research 
Laboratories™.). The pSC cells were plated in full serum media, placed in the incubator 
and allowed to attach for 5 hr.  The media was removed, washed with Dulbecco’s 
Phosphate-Buffered Saline (DPBS) and transferred to serum free media. After 12 hr in 
serum free media, cells were treated with the selected concentration of PA complexed 
with BSA as described previously [35, 64].  PA (Sigma-Aldrich, St. Louis, MO) stock 
was prepared in 100% ethanol at a concentration of 300 mM.  Fatty acid-free BSA (EMD 
Biosciences, San Diego, CA) was used as a buffer to ensure that concentrations of 
unbound free PA in the media were in the 10 nM range during the course of incubation 
[35].  In brief, serum free medium containing 150 µM fatty acid-free BSA was prepared 
and warmed up to 37
º
C to aid in the complete disassociation of PA.  Once media was 
warm, PA stock was added while vortexing to avoid crystalization of PA.  A final 
treatment concentration of 300 µM PA (PA:BSA, 2:1) was used.  Treatment media was 
place in the water bath at 37
º
C for 30 min before it was added to the cells. 
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Cell Viability Assays 
 
Crystal Violet Assay  
 
Briefly, pSC cells were plated in 96 well- tissue culture plates coated with Poly-L 
lysine (0.1%) (Sigma-Aldrich, Inc., St. Louis, MO), at a density of 1.0 x 10
4
 cells/well.  
Subsequent to 0, 24, 48, 72, 96 hour treatments with PA, 100 µl/well of 4% 
formaldehyde was added.  Following a 5 min incubation period at room temperature, the 
fixative was removed. Cells were post-fixed with 4% formaldehyde for another 30 min.  
PSC cells were then washed twice with distilled water and allowed to dry completely.  
Once dried, 100µl/well of crystal violet dye (Accustain®, Sigma-Aldrich) was added and 
incubated for 30 min at room temperature.  Cells were washed with distilled water to 
remove any unbound stain and dried.  The bound crystal violet was then dissolved with 
100µl/well of 10% acetic acid solution and place in rocker for 10 min at room 
temperature. The plate was analyzed by µQuant (Bio-Tek Instruments, Winooski, VT) 
using an optical density (O.D.) of 570 nm.  Data was examined using KCjunior™ 





Hoechst 33258 dye was used to assess chromatin condensation in iSC cells. The 
dye (10 µg/ml) was added to the cells and incubated for 10 min at 37
º
C with 5% CO2.  
The nuclear morphology of cells was observed and photographed using an Olympus 
fluorescent microscope (excitation/emission wavelength of 365/420 nm).  Cells 




Assessment of Apoptosis by Flow Cytometry 
 
Annexin V (BD Biosciences, San Diego, CA) and 7AAD (eBioscience, San 
Diego, CA) were used to detect apoptotic changes occurring in PA-LTx in pSC cells.  
PSC cells (1.25 x 10
4
) were plated in a 6 well Poly-L lysine plate.  After treatment, cells 
were trypsinized and collected.  They were then resuspended in 40 µl of binding buffer 
with 2 µl Annexin V FITC.  Cells were incubated for 15 min in the dark at room 
temperature.  After incubation, 160 µl of binding buffer and 2 µl of 7AAD were added.  
The cells were incubated for 5 min and additional 200 µl of binding buffer was added.   
Before analyzing, cells were filtered through a cell strainer cap that was fitted to a 
polystyrene round bottom flow cytometric tube. Cells were analyzed using the Becton-
Dikinson  FACSCalibur®  flow cytometer (Becton-Dikinson, San Francisco, CA).  A 
total of 100,000 events were measured per sample.  Annexin V was detected in the FL-1 
channel (530/30nm) while 7AAD was detected in FL-3 channel (650nm).  Data was 




Analysis of Mitochondrial Membrane Permeabilization 
  
Disruption of the mitochondrial membrane potential was assessed using the 
lipophilic cationic probe 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylben-zimidazol-
carbocyanine iodide (JC-1, MitoScreen kit, BD Biosciences) as described previously 
[64]. Briefly, unfixed cells were washed with PBS and resuspended in 1X JC-1 assay 
buffer supplemented with 10 µg/ml of JC-1. Cells were then incubated for 15 min at 
37
º
C, washed, and resuspended in 1X JC-1 assay buffer for immediate analysis using the 
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FACSCalibur® software program.  JC-1 in healthy cells aggregated in the mitochondria 
and was detected in the FL-2 channel while JC-1 with depolarized mitochondria 
membrane potential demonstrated a reduced fluorescence in the FL-2 channel. The 
percentage of cells with disrupted mitochondrial membrane potential was calculated 







To measure the [Ca
++
] in ER during PA treatment, the Fluo-4 NW Calcium Assay 
kit (Invitrogen) was used.  Briefly, 1.0 x10
4
 cells were plated in 96 well poly-D- lysine 
coated plates. Cells were treated accordingly.  Afterward, 90 µl of the dye, which 
included Probenecid (2.5 mM) was added to each well.  The plates were incubated at 
37
º
C for 30 min.  In the last 2 min of incubation thapsigargin (1µM) or DMSO (vehicle) 
(10ul/well) was added to the cells in order to deplete Ca
++ 
from the ER. Cells were 
analyzed using the Envison HTS Microplate reader (Perkin-Elmer ® Life and Analytical 
sciences, Shelton, CT).  Excitation/emission parameters were 480 nm and 510 nm 
respectively.   
 
 
Reactive Oxygen Species (ROS) Detection 
 
Detection of oxidative stress was done by staining the pSC cells with 20 µM of 
2’, 7’ dichlorodihydrofluorecein deacetate (H2DCFDA, Invitrogen) for 20 min at 37
º 
C.   
Cells were then detached by trypsinization and washed twice with DPBS. After filtered 
through cell strainer cap, cells were analyzed using a FACSCalibur® flow cytometer.  A 
total of 10,000 events were measured per sample.  Excitation/Emission wavelengths were 
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488 nm and 530/30 nm respectively.  Data was collected in log scale and analyzed using 
Cell Quest Pro® software and Flow-Jo® software.  
 
 
Analysis of Lysosomal Membrane Destabilization 
 
Acridine Orange (AO, Sigma Aldrich, St. Louis, MO) was used to examine 
lysosomal membrane destabilization (LMD).  AO, which is permeable to the cell and 
accumulates in the lysosome, due to proton trapping, emits a red/orange fluorescence at 
high concentrations (lysosomes) and green fluorescence at low concentrations (nucleus 
and cytoplasm). Cells with intact lysosomes demonstrate red speckles while cells with 
compromised lysosomes show a yellow diffused color. 
Briefly, AO (5 μg/ml) was added to pSC culture media and counterstained with 
Hoechst 33342 (1 μg/ml) for 20 min at 37°C. Cells were then examined under an 
Olympus BX50 epifluorescence microscope using a water immersion objective. Images 
were acquired using a digital Spot camera system.  Flow cytometry using AO was also 
utilized. PSC were stained with AO (5 μg/ml) in culture media for15 min at 37
0
C.  After 
the incubation period, pSC were washed twice with PBS and trypzinised.  SCM (2ml) 
was used to stop the trypzinization process and centrifuged at 6,000 rpms for 5min. Cells 
were resuspended and washed with PBS and centrifuged for another 5min.  The cellular 
pellet was resuspsended with 500µl of PBS and filtered through cell strainer cap.  Cells 
were analyzed using a FACSCalibur® flow cytometer.  Ten thousand events were 
collected and recorded on a logarithmic scale using the Beacon Dickinson FACScan 
instrument (excitation 488nm (argon laser).  Detectors for the green (FL1) and red (FL3) 
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fluorescence were utilized to identify cells with intact lysosomes (FL-3 positive) or 
disrupted lysosomes (Fl-3 negative).  
 
 
Detection of Cathepsin L and B Activity 
 
The detection of Cathepsin L and B activity was examined by using the 
fluorogenic substrate-based assay Magic Red L MR-(FR)2 and (MR-(RR)2 for cathepsin 
L and cathepsin B, respectively (Immunochemistry Technologies, Bloomington, MN). 
Magic Red was reconstituted with DMSO and further diluted (1:5 ratio) with distilled 
water. Treated pSC were exposed to Magic Red substrate (for 20min) and counterstained 
with Hoechst 33342 (for 5 min) and washed once with medium. Cells were examined 
under an Olympus BX50 epifluorescence microscope using a water immersion objective. 
Images were acquired using a digital Spot camera system.  
 
 
Caspase Activity Assays 
 
Assays to examine caspase 3/7 were performed on pSC treated with PA.  Cells 
(10,000 /well with the addition of 100ul of SCM/well) were plated in 96 well Poly-L 
lysine coated plate and treated with PA.  Caspase-Glo® 3/7 assay kit (Promega, Madison, 
WI) was utilized as well as Caspase 3 inhibitor (Promega, Madison, WI). Briefly, 
Caspase –Glo® 3/7 substrate was activated with Caspase-Glo® 3/7 buffer, in addition to 
the preparation of 1mg/ml of caspase inhibitor.  After the completion of treatment, 
50ul/well of media was removed for pSC and replaced with 50ul/well of substrate or 
substrate plus caspase 3/7 inhibitor.  The plate was then placed on a shaker and protected 
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from light at room temperature for 1H.  Cells were analyzed using the MicroLumatPlus 
illuminometer and quantified using the Win Glow Software.  
 
Statistical Analysis 
All the experiments were repeated independently at least three times. Values 
represent means ± SD.  Statistical comparisons were made using One Way ANOVA with 
Bonferroni’s Multiple Comparison test.  Significance was accepted at p < 0.05. 
 
Results 
PA Decreases Cell Viability and Induces Apoptosis in pSC Cells  
Cultured in Different Glucose Concentrations 
 
Normal metabolic functions require a balance of cellular FFAs and glucose 
concentrations [12, 214-215].  Studies have demonstrated that chronic and elevated levels 
of FFAs result in tissue toxicity and cellular death, also known as LTx [12, 14, 21-23, 84, 
216]. 
Our laboratory has shown that the ratio of PA:BSA 2:1 was able to generate a 
10nM range of unbound FFAs, a concentration observed  in conditions such as diabetes 
and  ischemia, that was able to induce LTx in nerve growth factor differentiated PC12 
cells, cortical cells and iSCs [35, 41, 64, 157-159, 213].     
 PSC were cultured in different concentrations of glucose, 5.5mM (euglycemic) or 
17mM (hyperglycemic), for 5 days prior to exposure to PA.  To identify the effects of 
glucose alone on pSCs, cell viability assays using crystal violet and Hoescht staining 
where performed at 96H following the 5 day incubation period with their prospective 
glucose concentrations.  Our results demonstrated that glucose alone did not cause a 
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significant amount of cell death to pSC (Figure 1A).  In addition, nucleic staining 
revealed normally dispersed chromatin with an intact cellular membrane (Figure 1B). 
However, the addition of PA (300µM) triggered apoptotic changes, such as chromatin 
condensation, DNA fragmentation, and apoptotic bodies that were detected by Hoescht 



















Figure 1: Analysis of pSC viability and the affects of PA on cellular morphology.  pSC 
cells were cultured in medium containing 5mM (euglycemic) or 17 mM glucose 
(hyperglycemic) for 5 days before the addition of PA.  After 5 days of pre-conditioning 
(A) crystal violet cell viability assays detected no significant cell death in euglycemic and 
hyperglycemic controls (BSA+0.1% ETOH) (B) To determine nuclear morphology, 
Hoescht staining was performed after 72H of PA:BSA 2:1 treatment. Nuclear 
condensation is indicated with white arrows. Representative micrographs were taken of 
four independent experiments. Statistical analysis was performed using one way ANOVA 





To further understand the effects of PA on pSC, a time course using crystal violet 
assays and AnnexinV/ 7AAD flow cytometric analysis were performed (Figure 2A). 
demonstrates a significant decrease in cell viability at 24H and 48H in pSC cultured in 
euglycemic and hyperglycemic environments, respectively.  To confirm PA’s induction 
of apoptosis, the established flow cytometric methods using Annexin V FITC and 7 AAD 
to measure early (Annexin V positive cell populations) and late apoptosis (7AAD 
positive cell populations) were performed.   Upon closer inspection, our study revealed a 
significant amount of apoptosis (5.38% early apoptosis ± 1.58 and 3.92% ± 0.957late 
apoptosis) at 24H in euglycemic cells increasing by 72H (22.00% ± 11.68 early 
apoptosis, and 6.07 % ± 1.57 late apoptosis).  In hyperglycemic conditions a significant 
amount of cell death (3.17% early apoptosis ± 0.78, 5.25% ± 2.35 late apoptosis) was 
observed at 12H and continued to increase at 72H (35.67% ± 7.87 early apoptosis, 12.17 






















Figure 2: Time course of PA-LTx induction of apoptosis in pSC.  Crystal violet and 
Annexin V/7AAD flow cytometric assays  were performed at different time points on PA 
treated pSC cells cultured in (A and B) euglycemic and (C and D) hyperglycemic 
conditions. Early apoptotic translocation of phosphotidyl cistein to the outer cell 
membrane renders the cell Annexin V+, while late apoptosis is detected by entry and 
retention of 7AAD in the nucleus. The percentages of cells that are Annexin V-/7AAD- 
(non apoptotic). Annexin V +/7AAD- (early stage apoptosis) and Annexin V+/7AAD+ 
(late stage apoptosis) are graphed. Statistical analysis was performed using one way 




PA-LTx Affects the ER and Results in an 
Increase in Intracellular Calcium 
 
 Borradaile, et al., (2006) demonstrated  that PA (500µM ) was able to incorporate 
itself into the membrane lipid rafts in the ER of  Chinese hamster ovarian cells, causing 
injury to the ER membrane and  resulting in the efflux of Ca
++
 from the ER ([Ca
++
 ]ER) 
into the cytosol [24].  This study found a significant decrease in [Ca
++
]ER within the first 
5H of PA treatment.  In accordance this study, our data shows that PA also caused an 
early dysfunction of the ER with a significant decrease in [Ca
++
]ER stores as early as 3H 
in euglycemic and 15min in hyperglycemic conditions (23.62 ± 5.85%  and 23.59 ± 
2.39%  reduction in [Ca
++



























Figure 3: PALTX reduced Ca
++
 concentration in the ER and increases mitochondrial 
depolarization in pSC.  (A) pSC cells were cultured in 5 mM or 17 mM glucose and 
treated with PA:BSA 2:1. [Ca
++
]ER, reference to control level, was determined at 5, 15, 30 
min and 3, 6, 12, 24 H after treatment. Mitochondrial membrane depolarization was 
examined by flow cytometric analysis using JC-1 fluorescent dye in (B) euglycemic and 
(C) hyperglycemic conditions in combination with  PA:BSA 2:1 treatments.  Quantitative 
analysis of JC-1 data using Flow JO® software is shown. Statistical analysis was 





Mitochondrial Depolarization Follows 
ER Stress Damage in PA-LTx 
 
To assess mitochondrial membrane potential and the overall health of the 
mitochondria, JC-1, a lipophilic, cationic dye was used [217-218].  JC-1 assays using 
flow cytometric analysis demonstrated a significant amount of MMD in pSC treated with 
PA at 6H in euglycemic cells and 1H in hyperglycemic cells (1.72 ± 0.22 and 1.97 ± 0.68 
fold of control respectively) (Figure 3A,3B).  Interestingly, a significant amount of MMD 





PA-LTx Induced an Augmented State 
of Oxidative Stress in pSC 
 
To assess the generation of ROS on PA treated pSCs, 2’7’ 
dichlorodihydrofluorecein dictate (H2DCFDA) was used and analyzed through flow 
cytometry.  A time course of 0, 3, 6, 12, 24, 48H  was performed following PA exposure.  
Our data demonstrates that different glucose concentrations alone did not increase 
reactive oxidative stress (ROS) levels (Figure. 4A).  However, once PA was administered 
an increase in ROS levels was detected at 12H in euglycemic and at 3H in hyperglycemic 
























Figure 4: PA-LTx increases ROS in pSC cultured in euglycemic and hyperglycemic 
conditions. ROS was observed using  H2DCFDA and analyzed through  flow cytometry.  
PSC cells were cultured in euglycemic (5 mM glucose), and hyperglycemic (17mM 
glucose) conditions for 5 days prior to PA treatment (PA:BSA 2:1). The increase in 
fluorescence is indicative of an increase in ROS levels within the cell. Cells treated with 
300 μM of H2O2 for 15 min were used as a positive control. No increase in ROS was 
observed in pSC cultured in different glucose concentrations alone (A). However, 
following PA treatment pSC cultured in (B) euglycemic and (C) hyperglycemic 
conditions demonstrated a significant increase in ROS levels as early as 12H in 
euglycemic and 3H in hyperglycemic conditions. Flow cytometry data was quantified 
using Cell Quest Pro® and Flow-Jo® software. Statistical analysis was performed using 




Lysosomal Involvement During PA-LTx 
Other studies and previous work in our lab have demonstrated that PA-LTx can 
induce lysosomal membrane destabilization (LMD) that can lead to protease release into 
the cytosol, resulting in cellular damage [39, 63, 70].  Acridine orange (AO) is able to 
detect LMD through its red/ green fluorescence when stimulated by green light [219-
220].  PSC cells were treated with PA at 0, 15min, 30min, 1, 3, 6, 12, 24, 48, and 72H 
and analyzed by flow cytometry.  Interestingly, our data suggests an early induction of  
LMD  in euglycemic pSC that begins at 3H and  reaches a peak at 72H after treatment 
(1.83± 0.46, 4.69± 1.36 fold of control, respectively) Figure 5A.  In contrast, LMD  in 
hyperglycemic conditions was not detected until 24H after PA treatment and reached a 
peak at  72H (Figure 6A) (2.41 ± 0.58 fold of control, 7.09 ± 2.56 fold of control, 
respectively).  
Fluorescent microscopy analysis of LMD and the possible release of cathepsins 
into the cytosol were also performed with AO or Magic Red for cathepsin B or L.  Magic 
red uses the cresyl violet fluorophore that becomes fluorescent upon cathepsin B or L 
cleavage.  Fluorescent microscopy with AO revealed LMD at 6, 12 and 24H after PA 
exposure in pSC cultured in euglycemic environment. (Figure 5B)  However, in 
hyperglycemic conditions, observable LMD occurred after 12H of PA treatment (Figure. 
6B).  Furthermore, protease activity, like cathepsin B and L were significantly observed 




















Figure 5: PA-LTx induces lysosomal membrane destabilization (LMD) in pSC  cultured 
in euglycemic conditions.  (A)Time course using acridine orange (AO) and flow 
cytometric analysis was used to quantify LMD in  euglycemic pSC.  Flow cytometric 
analysis demonstrates LMD as early as 3H after PA treatment. (B) AO staining was 
performed in pSC  0, 6, 12, 24H, in addition to Magic red staining for cathepsin B [221] 
and L (C.b) activity at 24 and 48 hours. Cells were counterstained with Hoechst staining 
and examined by fluorescent microscopy. Merged images are shown. Representative 
micrographs were taken of five independent experiments. Flow cytometry data was 
quantified using Cell Quest Pro® and Flow-Jo® software. Statistical analysis was 
performed using one way ANOVA with Bonferroni's exclusion test t.*p< 0.05, **p< 
























Figure 6:  PA-LTx induction of lysosomal membrane destabilization (LMD) in pSC  
cultured in hyperglycemic conditions.  (A) Flow cytometric analysis using acridine 
orange (AO) to examine LMD in pSC.. Flow cytometric analysis demonstrated a 
significant increase in LMD at 24H after treatment.  (B) AO staining was performed in 
pSC  0, 6, 12, 24H, in addition to (C) Magic red staining for cathepsin B [221] and L 
(C.b) activity at 24 and 48 hours. Representative micrographs were taken of five 
independent experiments. Cells were counterstained with Hoechst staining and examined 
by fluorescent microscopy. Merged images are shown. Flow cytometry data was 
quantified using Cell Quest Pro® and Flow-Jo® software. Statistical analysis was 










PA-LTx Induced Caspase 3/7 in pSC 
 
The activation of caspases has been shown to be a characteristic of PA-LTx [35, 
64, 222].  Therefore, caspase 3/7 activity was examined to further confirm and 
understand the mechanism of apoptosis by PA-LTx.   In euglycemic conditions, caspase 
3/7 activity significantly increased at 12H (3.62± 0.47 fold relative to control) (Figure. 
6A).  In hyperglycemic conditions, an early activation of caspase 3/7 activity (3H) was 
demonstrated (1.59 ± 0.18 fold induction) with levels reaching 4.72 ± 0.26 fold of control 























Figure 7: PA-LTx induces caspase 3/7 activation in pSC cultured in euglycemic and 
hyperglycemic conditions.  A colometric assay analyzing caspase 3/7 activity was 
performed on pSC cultured in (A) euglycemic and (B) hyperglycemic conditions and 
treated with PA:BSA 2:1 for 0, 15 min 30min, 1, 3, 6, 12H. The data demonstrates a 
significant detection of caspase 3/7 activity at 12H and 3H in euglycemic and 
hyperglycemic conditions respectively.  Statistical analysis was performed using one way 







Peripheral neuropathy (PN) is a debilitating complication experienced by many 
individuals, including those with type 2 diabetes [223-225].  Many studies on the 
development of diabetic peripheral neuropathy have focused on hyperglycemia and its 
detrimental effects on SCs [120, 160]. However, research is attempting to uncover the 
potential role of lipids in the induction of such disorders [12, 84, 213]. 
Elevated and chronic levels of plasma FFAs can result in a derangement of 
cellular function that can  lead  to the injury and death of the affected cell  [153-156].  
Damage to SCs can lead to segmental demyelination and axon atrophy, which are 
disorders that are associated with axonal degeneration and neuropathies [226].  This 
study sought to comprehend the contributions of PA-LTx in SC dysfunction and the 
possible association it may have to segmental demyelination and the development of 
peripheral neuropathies.    
Our data demonstrated that elevated levels of glucose alone did not result in 
observable pSC injury.  However, when exposed to PA, pSC underwent PA-LTx that 
resulted in apoptotic cellular changes and significant amounts of cell death beginning at 
24H in euglycemic and 12H in hyperglycemic conditions.  Furthermore, it was found that 
PA was able to incite a marked decrease in [Ca
++
]ER, induce MMD, LMD injury and 
generate an increase in cellular  ROS levels in both euglycemic and hyperglycemic 
environments. Of significance, hyperglycemic pSC seemed to demonstrate an altered 
sequence of events as an earlier injury to the ER, the mitochondria, and significant 
increase in caspase activity and ROS levels followed LMD.   
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In agreement with previous studies, the findings of our investigation also pointed 
to the detrimental effects of PA on cellular function [35, 64, 227-228].  A significant 
finding of this study is that it reports for the first time that elevated levels of glucose in 
the context of PA-LTx enhance the injury process by altering the sequence of events 
associated with this process in pSC. 
The main role of hyperglycemia in the injury to SCs and axons that leads to the 
development of peripheral neuropathy has been debated for a long time.  It has been 
suggested that hyperglycemia alone is able to increase oxidative stress and cause 
mitochondrial dysfunction in SCs resulting in peripheral neuropathy [102, 229].  
However, others have observed that glucose alone was unable to significantly increase 
ROS levels or induce apoptosis in SC or DRG models [108, 170].  Gumy, et al., (2008) 
found that hyperglycemia affected SC proliferation, migration, and hindered axonal and 
SC regeneration, but did not induce apoptosis [108].  In accordance to these studies, our 
lab did not detect a significant decrease in cell viability or an increase in ROS levels in 
pSC cultured in elevated levels of glucose alone.  It is believed that pSC cultured in a 
hyperglycemic condition may possess the ability to adapt to the mild and chronic 
stimulus presented by glucose.  A study by Vincent, et al., (2009) found that the adaption 
of DRGs to elevated levels of glucose is achieved by reducing aconitase and increasing 
antioxidant levels, thus decreasing  cellular stress [90].  Studies have suggested that upon 
encountering a mild and chronic insult, cells can initiate pro-survival as well as pro-
apoptotic pathways simultaneously.  Thus, the fate of the cell is decided by the stronger 
of the two pathways [90, 170-172].  Nevertheless, the discrepancy between the studies 
may be explained by considering the concentrations of glucose being utilized, the period 
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of time the cells are exposed to elevated glucose levels and the type of SCs (embryonic 
vs. adult) that are used in the study. 
 Since glucose alone did not affect cell viability or increase ROS levels, our  focus 
was on discerning the mechanism of PA-LTx in pSC . A time course using crystal violet 
and Annexin V/7AAD, assays were performed after PA treatment. The results show that 
a significant amount of apoptosis occurred in pSC cultured in euglycemic and 
hyperglycemic conditions after PA treatment.  The toxicity and the reduction of cell 
viability brought upon by PA treatment can be explained in three forms. 1) PA is a long 
chain saturated fatty acids (LCSFFA) that lacks double bonds and can tightly compact 
itself into lipid membrane rafts. The compaction of PA into lipid membrane rafts can 
result in a less flexible and rigid membrane that losses its ability to function properly 2) 
esterification of LCSFFA is less efficient, leading to the accumulation of nonesterefied 
FAs in the cytosol and resulting in organelle injury and cellular dysfunction 3)  LCSFFA 
generate toxic by-products such as diaglycerides and ceramides which can also result in 
cellular failure [24, 28, 176, 230].   
The next series of experiments focused on elucidating the mechanisms of PA-LTx 
on pSC.  Studies have demonstrated that PA is able to injure the ER early on, generating 




]i) and activating cell death pathways [39, 79, 
182].  A study performed in human beta cells and MIN6 cells found that a 10min 
exposure of PA (100uM) caused a rapid increase of [Ca
++
]i [231].  The affects of PA on 
the ER were  also observed in Chinese hamster ovarian cells which demonstrated that 
500uM PA exposure is able to significantly induce a decrease in [Ca
++
]ER  stores  as early 
as 5H after treatment and is followed by release of chaperones, such as GRP78, into the 
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cytosol [24].   In accordance to these studies, our data demonstrates that in euglycemic 
pSCs a significant decrease in [Ca
++
 ]ER was observed after 3H of PA (300uM) treatment 
(Figure. 3A).  By contrast, hyperglycemic pSCs exhibited an earlier depletion of [Ca
++
]ER 
stores detected as early as 15min after PA exposure (Figure 3A). 
 Current research has elucidated different pathways in the attempt to explain the 
rapid affect of PA on cellular Ca
++
 homeostasis and ER damage.   Borradaile, et al (2006) 
demonstrated that elevated levels of PA  accumulated in the lipid membrane rafts of the 
ER leading to membrane rigidity, loss of membrane fluidity  and  ER dysfunction [24].  
Yet, a study using hypothalamic neurons found that a 4H PA exposure lead to an increase 
JNK phosphorylation leading to FOXO1 activation and the possible upregulation in the 
transcription of pro-apoptotic genes that can induce ER  stress [51, 53]. Furthermore, 
other studies have suggested that PA can also stimulate voltage-sensitive channels that 
result in Ca
++
 influx from the extracellular environment causing an amplification in the 
concentration of intracellular Ca
++
 and leading to the activation of cell death pathways 
[231-233].  
Interestingly, following the injury to the ER by PA, the cell death pathways of 
pSCs cultured in euglycemic environments diverge from pSC cultured in hyperglycemic 
conditions.  Our results revealed that pSCs cultured in euglycemic environments and 
exposed to PA resulted in an increase in [Ca++]i, followed by LMD, MMD, ROS 
production and  caspase 3/7 activation.  However, in hyperglycemic conditions, pSCs 
exhibited an earlier involvement of the ER, followed by MMD, ROS, production, caspase 
3/7 activation and a late emergence of LMD.  Our data suggests a modification in the 
cascade of events following PA-LTx by hyperglycemic conditions.  
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 Previous studies in our lab found that  LMD is an early event of PA-LTx and the 
inhibition of cathepsin L significantly inhibited MMD and apoptosis in nerve growth 
factor differentiated PC12 cells (NGFDPC12) [41].  In addition, Li, et al.,( 2008) 
demonstrated that PA was able to cause lysosomal damage which resulted in the release 
of cathepsin B into the cytosol, thus triggering mitochondrial dysfunction and an increase 
in ROS production [39].  In euglycemic pSCs exposed to PA, our data appears to support 
such pathway since LMD precedes MMD, ROS production and caspase 3/7 activation.  
Feldstein, et al (2006) found that a 3H PA exposure to mouse hepatocytes was able to 
induce the translocation of Bax to the lysosome causing LMD the release of cathepsin B, 
leading to MMD and caspase activation. The mechanism of PA activation of Bax remains 
unclear, however, this study found that the induction of Bax is not specific to PA, as 
another LCSFFA, stearic acid, had similar effects.  In addition, the treatment with 4-
bromopalmitate did not prevent Bax translocation to the lysosome [70].   To take this a 
step further, elevated levels Ca
++
  have also been associate with the activation and 
translocation of Bax to membranes resulting in permeabilization  [234-235].  In 
summary, the upstream LMD may be through 1) the direct activation of Bax by PA or 2) 
a consequence of ER injury and the increase in [Ca
++
]i  after PA exposure, thus activating 
Bax .  It is also possible that PA may be incorporating itself in the ER and at the same 
time stimulating Bax.  The increase in [Ca
++]
i ,which along with Bax, is also able to 
destabilize the lysosome causing a release in cathepsins.  It is possible that the increase in 
[Ca++]i and the release of cathepsins by the lysosome can injure the mitochondria, 
resulting in ROS production, caspase activation and cell death.    
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However, our data found that in pSC cultured in hyperglycemic conditions, a 
delayed in LMD was observed after PA exposure.  Similarly, Russell, et. al., (1999) 
observed that in diabetic rats, apoptotic changes were detected in DRGs and SC, however 
lysosomes remained intact [236]. The alternation of events in hyperglycemic 
environments can be explained in three ways 1) the ER’s proximity to the mitochondria, 
thus injuring the mitochondria first 2) hyperglycemic stabilization of the lysosomal 
membrane and 3) affects  of hyperglycemia on lysosomal enzymes.   
 The functional and physical interactions between the mitochondria and the ER 
have been described by many.  Studies have suggested that the transfer of Ca
++
 from the 
ER to the mitochondria occurs in “hot spots” or areas where the ER and the mitochondria 
are in close approximation [237].  Czardas, et al., (2006) demonstrated that the increase 
in the approximation of the mitochondria and the ER resulted in the increased sensitivity 
of the mitochondria to Ca
++
 overload and activation of cell death pathways [184, 238].  
Therefore, it possible that the robust and earlier release of Ca
++
 from the ER is able to 
significantly overload the mitochondria matrix causing an early MMD, activation of 
caspases and production of ROS prior to the destabilization of the lysosome.    
A second explanation may be the stabilization of the lysosomal membrane by 
elevated glucose levels.  Studies have found that levels of Hsp70, a stress induced protein 
that promotes cell survival by inhibiting LMD , were significantly higher in diabetic 
patients [42, 239].   It is suggested that Hsp70 binds to the  endolysosomal anionic 
phospholipid bis (monoacylglycerol) phosphate (BMP) which can then inhibit the activity 
of acid shingomyelinase [240-242]. Thus, it is possible that the delay in LMD found in 
hyperglycemia pSC may be through the possible upregulation of Hsp70.  
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In addition, hyperglycemia has also been shown to affect lysosomal enzymes and 
reduce the low molecular pool of iron radicals resulting in lysosomal stabilization [243].   
Studies have found a decrease in lysosomal enzyme activity like, cathepsin B and L, in 
tissues of diabetic streptozotocin rats [244-245].  In addition, through the production of 
advance glycation endproducts  the reduction of lysosomal enzyme activity in retinal 
pigment epithelium has been observed [246]. However, the exact mechanism on how 
glucose decreases lysosomal enzyme activity continues to be unclear.   
Glucose can reduce low molecular iron levels in lysosomes, thus rendering them 
more stable and less sensitive to insults.  It has been shown an increase in blood glucose 
levels was able to prevent or significantly reduce the toxic effects of alloxan, a glucose 
analogue used to induce diabetes in animals. It is believed that alloxan increases free 
radicals in β cells [247-248]. A  study conducted by, Olenjnicka, et al., (1999) observed 
that in alloxan treated animals, β cells cultured in low concentrations of glucose 
demonstrated higher redox active iron levels and signs of autophagy.  In addition, β cells 
were more sensitive to oxidative stress and exhibited unstable lysosomes. In contrast, 
cells cultured in a hyperglycemic condition had a decrease in redox active iron and did 
not exhibit sighs of autophagy. Moreover, hyperglycemic β cells were less sensitive to 
oxidative stress and did not demonstrate LMD after alloxan treatments. The above study 
suggests that the stability of the lysosome may be directly correlated to the amount of 
intralysosomal redox active iron which is inversely proportional to glucose 
concentrations [249].    
The delay in LMD in hyperglycemic pSCs may explain the early and elevated 
levels of caspase 3/7 after PA treatment.  Han, et. al., (2010) found that inhibition of 
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autophagy in β cells cultured in chronic hyperglycemic conditions increased the 
activation of capase-3. Therefore, the lack of involvement of the lysosome in the 
apoptotic process may influence the cell to utilize an alternative pathway, resulting in the 
early and robust activation of caspases to initiate cell death [250].   
Our data suggests that hyperglycemic conditions place a chronic and mild insult 
on pSC.  However, a second insult, such as the addition of PA, will drive the pSC beyond 
its capacity to survive, resulting in ER injury and an early and robust release of Ca
++ 
into 
the cytosol. Due to the close approximation of the mitochondria to the ER, the 
mitochondrial matrix will undergo Ca
++
 overload resulting in MMD.  The increase in 
mitochondrial damage leads to ROS production and an increase in caspase activation 
initiating cellular death.  A prolonged PA exposure (more than 24H) will override the 
hyperglycemic stability of the lysosome and LMD will occur releasing cathepsin B and L 
and further damaging the cell. 
Our studies have shown for the first time the ability of hyperglycemia to alter the 
cell death pathway initiated by PA-LTx.  The mechanism of hyperglycemic stabilization 
of lysosomes continues to be unclear. Further studies need to examine the influence of 
glucose, such as Hsp70 and iron, on lysosomal stability. In addition, early events such as 
JNK and Bax involvement also need to be addressed to further elucidate the effects of 
PA-LTx on pSC.  Understanding the mechanisms of PA-LTx in SCs is of great 
importance as the comprehension of these pathways can aid in the discovery of 
innovative therapies for the effective treatment and prevention of neuropathies, such 
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Elevated levels of free fatty acids (FFA) have been demonstrated in individuals 
suffering from obesity and type 2 Diabetes.  Chronic and high FFA concentrations can 
damage the nervous system leading to lipotoxicity (LTx) and neuronal dysfunction.  LTx 
is the pathological response of the cell to chronic and elevated levels of fatty acids.   Our 
lab is interested in determining whether LTx plays a role in the development of peripheral 
nerve injury resulting in peripheral neuropathy, a common complication of individuals 
who are obese and/or suffer from type 2 Diabetes. The focus of the present study is to 
determine whether pathological concentrations of palmitic acid (PA), a long chain 
saturated FFA, affects Schwann cell’s (SC) ability to produce and maintain adequate 
myelin protein levels for proper myelin formation. A disturbance in myelin formation 
leads to segmental demyelination resulting in peripheral neuropathy. Our experimental 
model is an immortalized Schwann (iSC) cell line that has similar morphology, 
immunohystochemistry, and gene expression features to primary rat SC. Due to its 
importance in myelin function, levels of peripheral myelin protein (PMP22) were 
analyzed.  ISC cells were cultured at glucose concentrations of 17mM and 50mM., to 
mimic a euglycemic and hyperglycemic state respectively. ISC were treated with PA 
dissolved in ETOH and Bovine Serum Albumin (BSA) (PA:BSA 2:1 (300uM/150uM)) 
in serum free media.  Real Time PCR (RTPCR) experiments demonstrated a 
downregulation of PMP22 mRNA levels within the first 12H of PA exposure which was 
more pronounced in iSC cultured in a hyperglycemic environment. Western blot analysis 
also demonstrated a significant decrease in PMP22 protein levels at 12H, which was 
more evident in hyperglycemic conditions.  A co treatment of PA with MCI-186, an 
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antioxidant used to reduce ROS concentrations prevented the downregulation of PMP22 
mRNA levels.  Our data suggests that the expression of PMP22 mRNA levels in iSC 
undergoing PA-LTx may be associated with cellular oxidative stress.  It is of importance 
to understand the effects of PA-LTx on myelin proteins in iSC in order to offer novel 
therapies to halt the development and the progression of peripheral neuropathies. 
 
Introduction 
Over 20 million people suffer from peripheral neuropathy, which is considered to 
be one of the most common and chronic diseases in the United States [75].  Peripheral 
neuropathy describes the neuronal dysfunction and damage caused by disease or trauma 
that leads to nerve conduction disturbances.   Adequate myelin compaction and formation 
are essential for proper nerve function.  In the peripheral nervous system Schwann cells 
(SCs) produce myelin, which enhances the nerve conduction velocity (NCV) of the axon.  
Myelin, the modified plasma membrane of the SC, wraps around the axon forming a 
cover called the myelin sheath.  The myelin sheath is composed of cholesterol, 
phospholipids, and proteins, such as protein zero (P0), myelin basic protein (MBP) and 
peripheral myelin protein 22 (PMP22).  The structures of SC membranes consist of 
integral proteins that are secured within the membrane and extrinsic proteins that are 
attached to the surfaces of the membrane.   As the cell myelinates, opposition from the 
two extracellular and cytosolic areas in the membrane come together, the glycolipids and 
myelin proteins in the membranes come closer and fuse providing the stability and 
compaction needed for proper myelin function. While proteins such as P0 and MBP are 
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necessary for myelin compaction, PMP22 is critical for myelin function, assembly and 
maintenance [119, 251-255].   
 Myelin increases axonal conductance by decreasing the energy requirements for 
axonal membrane depolarization, leading to an increase in conduction velocity.  
Therefore, the enhancement of the NCV allows for more advanced and accelerated 
processing to take place in the human nervous system.   
However, genetic and metabolic abnormalities can damage SCs resulting in the 
inadequate production, transportation and increased degradation of myelin proteins, 
which can lead to the development of peripheral neuropathies.  Studies have 
demonstrated that a decrease in myelin protein concentrations can lead to a decrease in 
myelin thickness, loose uncompacted myelin, myelin “loops” and infoldings/outfoldings 
leading to the accumulation of non functional myelin at the nodes of Ranvier [256-257]. 
A critical component of myelin is PMP22. PMP22 makes 2-5% of the total 
protein, it is considered to be one of the most important myelin proteins in the peripheral 
nervous system.  PMP22 mRNA levels are significantly downregulated in crush nerve 
injuries and upregulated during SC myelination [119, 258].  However, during the 
quiescent periods of the SC, approximately 80% of PMP22 is misfolded and degraded by 
the unfolded protein response in the endoplasmic reticulum (ER) [259].   
Studies have shown that the overexpression or underexpression of PMP22 affects 
myelin stability and function, resulting in peripheral neuropathies [252-253, 260-263].  
Charcot-Marie Tooth disease (CMT-1A) and autosomal dominant hereditary peripheral 
neuropathy with liability to pressure palsies (HNPP) are examples of neuropathies that 
are associated with PMP22 overexpression and underexpression respectively.  CMT-1A 
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is caused by a duplication of PMP22 gene that is found in human chromosome 17 [254, 
262].  Studies have demonstrated that PMP22 overexpression will form perinuclear 
aggregosomes in SCs resulting in the upregulation of the lysosomal pathway.  In 
addition, the accumulation and degradation of PMP22 in the cytosol can reduce its 
incorporation into myelin and contribute to the demyelination observed in CMT-1A [253, 
257].  Furthermore, the downregulation of PMP22 observed in HNPP is characterized by 
demyelination and hypermyelination of axonal areas called tomacula [263-264].   
Metabolic abnormalities can also lead to demyelination. Peripheral nerves of 
obese individuals and people with diabetes type 2 have also demonstrated segmental 
demyelination. Studies have observed “onion-bulb” formations, disruptions and 
ballooning of myelin sheaths in obese and diabetic animal models.  In addition, SCs were 
observed to have “reactive, degenerative and proliferative changes” in peripheral nerves 
of diabetic animal models [115, 229].      
Previous studies from our lab found that palmitic acid (PA), a long chain saturated 
fatty acid, induced lipotoxicity (LTx) that activated an apoptotic pathway in immortalized 
and primary Schwann cells [78, 213].  The pathological response of the cell to the toxic 
levels of fatty acids (FA) has been termed LTx [5, 22]. Our lab has also demonstrated that 
hyperglycemia is able to magnify the lipotoxic response [213].   Therefore, this study 
sought to elucidate the possible effects of PA-LTx on myelin proteins, such as PMP22 , 
in iSCs cultured in euglycemic and hyperglycemic conditions.    
Our data shows that iSCs exposed to PA demonstrated mRNA levels of PMP22 
that were downregulated in a time and concentration dependent manner. In addition, iSCs 
cultured in hyperglycemic conditions demonstrated an earlier downregulation of PMP22 
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mRNA levels when compared to euglycemic environments.  Western blot analysis 
demonstrated a decrease in protein levels that correlated with mRNA levels of PMP22. 
The co- treatment of PA and MCI- 186, an antioxidant, was able to significantly reduce 
oxidative stress and stabilize mRNA levels of PMP22.  Therefore, our study suggests that 
the expression of PMP22 mRNA levels in iSC undergoing PA-LTx may be mediated 







 Schwann cells used in this study were a generous gift from Dr. Laurel Bolin 
[148].  The immortalized SC clone (iSC) was shown to express markers specific to 
primary SC such as S100β, p75 
NGFR
 and Vimentin [148-151]  Cells were maintained in 
culture medium prepared from Dulbecco’s modified Eagle’s medium/Ham’s F12 
(DMEM/F12) 50/50 mix without glutamine (Mediatech, Herndon, VA).  This medium 
contains 17 mM glucose (i.e. the euglycemic condition for this study). Ten percent horse 
serum (Invitrogen, Carlsbad, CA), 2 mM L-glutamine (Mediatech), 100 units/ml 
penicillin and 100 µg/ml streptomycin (Mediatech) were supplemented to the media.  iSC 
cells were incubated at 37
º 
C with 5% CO2 .  Culture media was changed every three 
days. Cells were used at a maximum of 7 passages.   To achieve a desired hyperglycemic 
state of the culture media, we also prepared DMEM beginning with powder DMEM 
(Mediatech) without glucose, L-glutamine, phenol red, pyruvate or sodium bicarbonate.  
These were added at the appropriate concentrations after DMEM was dissolved in sterile 
deionized water. To make hyperglycemic media, 45 mM dextrose was supplemented.  
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Next, DMEM was filtered and mixed with equal volume of Ham’s F12 (contains 10 mM 
glucose) to make final DMEM/F12 (50/50) media with 50 mM glucose (hyperglycemic). 
Further, 10% horse serum, 2 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml 
streptomycin were also added.  
 
Fatty Acid Treatment 
Treatments were done in serum free media.  Serum free media consisted of 
DMEM/F12 (50/50), 2 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml 
streptomycin, and 1X N-2 supplement (Gibco, Invitrogen Corp.). The iSC cells were 
plated in full serum media, placed in the incubator and allowed to attach for 5 hr.  The 
media was removed, washed with Dulbecco’s Phosphate-Buffered Saline (DPBS) and 
transferred to serum free media. After 12 hr in serum free media, cells were treated with 
the selected concentrations of PA complexed with bovine serum albumin (BSA) as 
described previously [35, 64].  PA (Sigma-Aldrich, St. Louis, MO) stock was prepared in 
100% ethanol at a concentration of 300 mM. fatty acid-free BSA (EMD Biosciences, San 
Diego, CA) was used as a buffer to ensure that concentrations of unbound free PA in the 
media were in the 10 nM range during the course of incubation [35]. In brief, serum free 
medium containing 150 µM fatty acid-free BSA was prepared and warmed up to 37
º
C to 
aid in the complete disassociation of PA.  Once media was warm, PA stock was added 
while vortexing to avoid clumping of PA.  Two treatment concentrations were used: 150 
µM PA (PA:BSA, 1:1) and 300 µM PA (PA:BSA, 2:1).  Treatment media were place in 
the water bath at 37
º







Antioxidant MCI-186 (Biomol Research Laboratories, Plymouth Meeting, PA) 
was used to reduce ROS during PA-LTx. MCI-186.  MCI-186 was first dissolved in 
DMSO and warmed up to 37
º 
C to ensure the complete disassociation.  MCI-186 stock 
solution (or DMSO as a control) was then diluted into the PA/BSA treatment media to 
attain final concentration of 100 µM or 1 mM.   
 
RTPCR Experiments 
Total RNA was extracted using TRI-Reagent (Molecular Research Center, 
Cincinnati, OH).  RNA quantification was done by measuring O.D. at 260 nm and stored 
at -80
º 
C.  Two-step RT-PCR was performed. First, RNA (0.5~ 1µg) was used to make 
cDNA using the iScrip cDNA synthesis kit (Bio-Rad, Hercules, CA). Next, real-time 
PCR with Syber Green was conducted using CFX96 Real-Time System (Bio-Rad).  
PMP22 reverse primer was 5’CACTGTGTCTCACTGTGTAGATGGC3’ and forward 
primer 5’TGTCCCTGTTCCTGTTCTTCTGC’3. ß-actin was selected as a housekeeping 
gene (reverse primer 5’-GCG GCA GTG GCC ATC TC-3’ and forward primer 5’- GGG 
AAA TCG TGC GTG ACA TT-3’). The relative amount of mRNA was calculated using 




Protein extract from iSC were separate on a SDS-PAGE gel and 
electrophoretically transferred to a nitrocellulose membrane. After transfer, 5% milk in 
Tris-buffered saline (TTBS) with 0.05% Tween 20, PH 7.4 at room temperature for 1 hr 
 
162 
was performed to block the membrane.  Subsequently, the membrane was washed and 
then incubated with primary antibody against PMP22 (Abcam, Cambridge, MA) in TTBS 
1X containing 0.05% and Tween 20 at 4
0
C overnight.  The membrane wash washed three 
times with TTBS 1X and incubated with HRP-anti mouse (GE Healthcare Bioscience) for 
1 hr at room temperature, followed by three washes with TTBS. The signal was then 
detected by ECL-plus (GE Healthcare Bioscience).  
 
Statistical Analysis 
All the experiments were repeated independently at least three times. Values 
represent means ± SD.  Statistical comparisons were made using One Way ANOVA with 
Bonferroni’s Multiple Comparison test.  Significance was accepted at p < 0.05. 
 
Results 
PA-LTx is Able to Downregulate mRNA of PMP22 
 
Previous work demonstrated that PA-LTx was able to induce apoptosis in iSCs 
with significant cell death at 24 and 48Hrs [213].  To test the possible effects of PA-LTx 
on myelin genes, RTPCR experiments were performed to analyze changes in PMP22 
mRNA levels.  Our data demonstrates a significant decrease in mRNA concentration in 
iSCs treated with PA:BSA 2:1 ratio in  both euglycemic (17mM glucose) and 
hyperglycemic (50mM glucose) conditions (Figure. 1A and 1B).  After 6hrs of treatment, 
there was a 40% decrease in PMP22 mRNA levels that reached a 67% reduction at 12hrs 
in  iSCs cultured in a euglycemic environment.  In hyperglycemic iSCs a similar trend 
 
163 
was observed with a significant decrease in mRNA levels beginning earlier at 3hrs (45%) 


































Figure 1. Levels of PMP22 mRNA in iSC cells treated with PA  
Levels of mRNA were analyzed by RT- PCR.  (A) iSC cells cultured in euglycemic state 
(17mM glucose concentration) demonstrated a decrease in PMP22 mRNA levels 
following treatment with PA.  (B) A similar trend was demonstrated in iSC cells cultured 





PA-LTx Induces a Decrease in PMP22 Protein Levels 
 
Western blot analysis demonstrated a significant decrease in protein levels at 12hrs of PA 










































Figure 2: PA-LTx induced a decrease in protein levels of PMP22 
ISC were treated with PA:BSA 2:1 concentrations and analyzed for PMP22 protein 
concentrations.  Western blot analysis reveals a significant decrease in PMP 22 protein 





PMP22 mRNA Levels are Restored with the Addition 
of MCI-186 in PA-LTx iSC Cells 
 
PA-LTx significantly increase ROS levels as early as 3Hrs after treatment and 
peaks at 48H [213]. Previous work from our lab demonstrated that the addition of MCI-
186, an antioxidant, significantly reduced ROS levels and prevented cellular death during 
the first 24Hrs of PA exposure [213].  To better understand the role of ROS in the 
disturbance of myelin proteins, PMP22 mRNA levels were analyzed in the presence of 
MCI-186.  Our data demonstrates that PMP 22 mRNA levels in euglycemic cells co 
treated with 100uM MCI-186 and PA:BSA  2:1 were not altered through the 12H time 
course.  A significant drop was evident at 12hr 2:1 PA/BSA treatment with no MCI-186; 
however, this decrease was significant inhibited with the addition of MCI-186 (Figure 
3A).  In hyperglycemic cells co-treated with PA:BSA 2:1 and 1mM MCI-186 mRNA 



































Figure 3. PMP22 mRNA levels in iSC cultures treated with MCI-186.  iSC cells in A) 
euglycemic and B) hyperglycemic media were treated with PA with or without MCI-186. 
Cells in euglycemic media were treated with 100uM MCI-186, while cells in 
hyperglycemic media were treated with 1mM MCI-186.  Results demonstrate that MCI-
186 prevented the decline of PMP22 mRNA levels in both euglycemic and 








Proper levels of myelin proteins are required for precise myelin compaction and 
function.  Studies have shown that SC dysfunction can lead to a disruption of myelin 
proteins, such as PMP22, resulting in demyelination and the development of peripheral 
neuropathies, such as CMT-1A and HNPP.  Since, demyelination has also been observed 
in individuals demonstrating diabetic peripheral neuropathy, the purpose of this study 
was to investigate a possible disruption of PMP22 levels in SCs undergoing PA-LTx.    
The current study found that PA-LTx induced a significant downregulation of 
PMP22 mRNA levels in iSCs cultured in euglycemic and hyperglycemic conditions. In 
addition, earlier disruptions of mRNA levels were observed in a hyperglycemic 
environment.  Studies have shown that the manufacturing of proteins that are unnecessary 
for cell survival will become restrained when the cell encounters an insult, such as PA.  It 
is possible that PMP22 is not essential for cellular survival, thus its downregulation is 
initiated in cells undergoing PA-LTx.  
 However, ROS levels are also known to have the ability to influence gene 
expression [265].  A study found that ROS was able to regulate gene expression by 
activating different transcription factors, such as activator protein 1 (AP-1), which can 
affect cellular proliferation, differentiation and morphogenesis [265].  Our studies 
demonstrated that PA-LTx is able to significantly increase ROS concentrations in SCs 
cultured in euglycemic and hyperglycemic conditions [213].  Furthermore, other studies 
have shown that intracellular Ca++ disturbances can also play a major role gene 
expression [266-268].  Since, work from our lab found that PA-LTx resulted in elevated 
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intracellular Ca++ levels, the downregulation of mRNA concentrations of PMP22 may be 
due to factors such as AP-1 [213, 265].      
The downregulation of mRNA levels correlated with the decrease in protein 
levels of PMP22 after PA exposure.  A decrease in mRNA levels can directly affect 
protein expression in the cells, however, the disruption in protein expression can also 
involve the ER.  Studies have shown that upon ER stress, the unfolded protein response 
[44] or the ER- assisted degradation response [45] can be activated.  The purpose of the 
UPR and ERAD response is to relive the load on the ER by decreasing the translation of 
proteins and increasing the degradation of improperly folded proteins, respectively [3, 45, 
253].  Work from our lab found that PA-LTx is able to induce ER stress and activate ER 
stress genes [44].  Therefore, the decrease in PMP22 protein levels can be the result of 
the induction of the UPR or ERAD pathways.  
The co- treatment of MCI-186, an antioxidant, and PA was able to significantly 
reduce oxidative stress and prevent the downregulation of PMP22mRNA levels in iSC 
cultured in a euglycemic and hyperglycemic environments.  The decrease in ROS levels 
by MCI-186 may prevent oxidant damage and severe intracellular Ca
++
 disruptions, thus 
normal transcription of genes, such as PMP22, are able to be produced.   In conclusion, 
the ability of MCI-186 to stabilize PMP22 mRNA levels in PA-LTx iSC cells suggests 
that the regulation of PMP22 mRNA expression may be mediated through cellular 
oxidative stress.   
The current study demonstrates that 1) iSCs exposed to PA demonstrated a 
downregulation of mRNA levels of PMP22 in a time and concentration dependent 
manner 2) PA-LTx in hyperglycemic conditions exhibited an earlier downregulation of 
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PMP22 mRNA levels when compared to euglycemic environments 3) the co- treatment 
of PA and MCI- 186, an antioxidant, was able to significantly reduce oxidative stress and 
stabilize mRNA levels of PMP22 in euglycemic and hyperglycemic conditions.  
Therefore, our study proposes that the expression of PMP22 mRNA levels in iSC 
cultured in euglycemic and hyperglycemic conditions undergoing PA-LTx may be 
mediated through cellular oxidative stress.   
It is also suggested that a decrease in production or the increase in degradation of 
PMP22 can lead to the inability of this critical myelin protein to reach the plasma 
membrane of SCs. Thus, the inadequate levels of PMP22 in the membrane will yield an 
improper compaction of myelin, resulting in axonal demyelination and the possible 
development of peripheral neuropathy.  Furthermore, hyperglycemic conditions may 
magnify PA-LTx by driving the cell to a more severe and earlier cellular dysfunction.  In 
conclusion, the data supports the notion that elevated levels of FFAs may play a role in 
segmental demyelination through the disruption of myelin proteins, like PMP22, leading 
to the development of peripheral neuropathy.  
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Summary of Findings 
The present study explored the role of PA-LTx in SCs cultured in different 
concentrations of glucose. The aim of this study was to elucidate the potential 
contributions of FFAs in the development of peripheral nerve damage.  It is essential to 
understand the mechanisms of PA-LTx in SCs since this may lead to the development of 
innovative and effective therapies that will prevent or halt the progression of peripheral 
neuropathy, a common complication of diabetes type 2.  
Previous work from our lab demonstrated that PA and stearic acid, at 
concentrations similar to those found in traumatic brain injuries (FFA:BSA  2:1), were 
able to induce cellular death [64, 213].  By contrast, oleic and arachodonic acids showed 
no significant decrease in cell viability.  LCSFAs, such as PA and stearic acid activated 
caspase 3 and 8, and cleavage of poly (ADP-ribose) polymerase (PARP).  Toxicity by PA 
and stearic acid was found to be caspase independent and involved the disruption in gene 
expression of fas ligand/receptor [35].  Further work in NGFDPC12 and rat cortical cells 
showed that PA-LTx induced apoptosis, the ASCOS response, MMD, and an increase in 
BNIP3, a proapoptotic member of the Bcl-2 family.  Lysosomal membrane 
destabilization and cathepsin L leakage into the cytosol was detected and deemed 
imperative in the apoptotic process due to the hindrance in cell death with the addition of 
cathepsin L inhibitors [41, 64]. 
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The findings of this study demonstrated that exposure to high levels of PA, a 
LCSFA, resulted in a powerful lipotoxic response in immortalized and primary SCs.  
Both immortalized (iSC) and primary SCs (pSC) were cultured in euglycemic and 
hyperglycemic environments for 4-5 days before PA exposure to mimic a chronic glucose 
environment.  Furthermore, full serum media was changed to serum free before exposing 
cells to PA. This was done to remove any confounding factors that are added by full 
serum and to decrease the proliferation rate of the cells.   
In a euglycemic conditions the addition of PA decreased cell viability of iSC and 
pSC in a dose and time dependent manner.  The decrease of endoplasmic reticulum (ER) 
Ca
++
 stores was the first indication of PA cellular injury (approximately 1H after PA 
exposure). Lysosomal injury (3H) followed ER damage and included the release in 
cathepsin L and B .  A prolonged PA exposure to iSC and pSC resulted in mitochondrial 
membrane depolarization (6H) leading to a significant increase in reactive oxidative 
stress (ROS) (12H) and the activation of caspase 3 (12H).          
Upon a closer examination to the ER, PA-LTx induced the up-regulation of ER 
stress genes Xbp1 and CHOP mRNA levels, while significantly downregulating GRP78 
with increased cell death. In addition, mRNA and protein levels of myelin protein 22 
(PMP22) were also downregulated after PA exposure.       
Interestingly, it was observed that chronic hyperglycemia alone does not induce 
iSC or pSC cell death but its presence strongly magnifies that apoptotic process. In 
addition, 2’7’ DCF and JC-1 assays found no significant increase in ROS production or 
MMD with elevated glucose concentrations alone in both iSC and pSC.  However, upon 
the addition of PA, a robust and earlier detection of ER Ca
++
 efflux into the cytosol was 
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observed after 15min.  ER stress genes were also disrupted in iSC cells, with an up-
regulation of GRP78 mRNA and protein expression in the hyperglycemic state when iSC 
were undergoing cellular death.   
 In contrast to the euglycemic conditions, PA-LTx caused MMD (1H) and 
significantly increased ROS production (3H), and caspase activation (3H). After 24H of 
PA exposure, flow cytometric analysis was able to detect a significant LMD with 
cathepsin B and L release into the cytosol.   Similarly, PMP 22 mRNA and protein levels 
were decreased with PA treatments, however the downregulation of mRNA was 
significant at an earlier time when compared to euglycemic conditions.   Overall, the 
apoptotic events observed in hyperglycemic conditions were encountered at earlier time 
points when compared to euglycemic conditions, except for lysosomal injury.  The delay 
in lysosomal damage in hyperglycemic conditions continues to be unclear and needs to 
be further examined.      
In the attempt to understand the role of Ca
++ 
and ROS in cellular damage, a 
calcium chelator, BAPTA-AM, and an antioxidant, MCI-186, were used as a co-
treatment with PA.  Our study found that reducing excessive cytosolic Ca
++ 
levels with a 
Ca
++
 chelator (BAPTA-AM) inhibited cell death in euglycemic and hyperglycemic 
Schwann cells.  Furthermore, our data demonstrates that BAPTA-AM is able to reduce 
ROS level in both euglycemic and hyperglycemic iSC, thus possible suggesting a major 
role of Ca
++
 in the lipotoxic response.  Furthermore, BAPTA-AM resulted in the 
stabilization of mRNA levels of pro-survival genes such as GRP78, upregulation of  
XBP1 in a euglycemic and hyperglycemic conditions.  The decrease in pro-apoptotic ER 
stress genes such as CHOP was observed in both euglycemic and hyperglycemic 
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conditions.  The data indicates that reducing the stress on the ER may assist the cell in its 
attempt to survive.  To further examine the role of Ca
++
 in PA-LTx, the inhibition of N-
methyl D-aspartate (NMDA) receptors with D-AP5 was utilized as a co-treatment with 
PA. D-AP5 was able to increased iSC cell viability at 24H only in both euglycemic and 
hyperglycemic conditions.  
The antioxidant MCI-186 was able to significantly decrease oxidative stress in 
both euglycemic and hyperglycemic conditions and prevented the downregulation of 
mRNA levels of PMP22 in iSC during PA exposure.  MCI 186 also increased euglycemic 
and hyperglycemic iSC viability at 24 hours, however, MCI-186 could not prevent 
cellular death after a prolonged PA exposure greater than 24 hours.  
 
 
Proposed PA-LTx Mechanism 
 
The data generated by this study leads to the proposition of two distinct pathways 
of PA-LTx that is modulated by elevated levels of glucose. The first pathway involves 
the induction of PA-LTx in euglycemic conditions beginning with the injury to the ER 
causing the efflux of Ca
++
 into the cytosol. Weather PA directly or indirectly injures the 
ER membrane continues to remain unclear.  However, possibly through PA’s activation 
of proapoptotic proteins, such as Bax or thought the toxic release of Ca
++
 into the cytosol, 
LMD and the release cathepsins are the next events that occur after PA exposure. The 
release of cathepsins, in addition to the increase in cytosolic Ca
++
 may directly affect the 
mitochondrial membrane leading to MMD. The increase in ROS levels and caspase 
follows MMD, in addition to a decrease in PMP22 mRNA and protein levels possibly 
due to increase in ROS or the activation of the ER stress response.  Consequently, 
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cellular injury by PA-LTx will result in the initiation of apoptotic pathways leading to 
cell death.     
 The alternate pathway involves the influence of hyperglycemia in the cascade of 
apoptotic events.  Hyperglycemia alone can disrupt the cell by 1) modifying proteins and 
protein-DNA interactions 2) influencing FA metabolism by the accumulation of malonyl-
CoA 3) and disrupting the lysosomal degradation pathway [269]-[270].    However, if the 
insult is not great, the cells are able to readjust with the stress without cellular death [90].    
Nonetheless, the addition of a second insult can result in severe cellular damage.   
As observed in our study, the addition of PA to SCs cultured in hyperglycemia resulted in 
an early and strong ER response followed by MMD.  The earlier elevation of intracellular 
Ca
++
 may explain the early MMD observed in our study.   
The damage to the mitochondria can result in the generation of ROS and caspase 
activation. Since, SCs have already increased their production of factors such as 
antioxidants to cope with elevated glucose levels, the insult by PA may have pushed the 
SC to an earlier and robust generation of ROS. The increase in caspase activation may 
also be explained by the elevated levels of ROS and mitochondrial damage after PA 
exposure.  In addition, the disruption of PMP22 mRNA and protein levels at an earlier 
time can also be explained by the negative cellular influence of hyperglycemia.     
LMD occurred at a later time point in the lipotoxic process possibly due to the 
involvement of an increase in proteins secondary to hyperglycemia, such as the anti 
apoptotic chaperone heat shock protein 70 (Hsp 70).  The delay in lysosomal involvement 
may have contributed to a disruption in the autophagic process resulting in the strong 
increase in caspase activation that is observed in our studies.     
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In conclusion, the earlier and stronger elevation of levels of cytosolic Ca
++ 
concentrations, ROS levels, possible impairments to autophagic pathways due to 
lysosomal delay, and the release in cathepsins L and B, greatly increase the severity of 
SC damage. Figure 1. 

























Figure 1. Proposed Mechanisms of PA-LTx in Schwann Cells. 
Based on our studies, PA-LTx occurs in both euglycemic and hyperglycemic conditions 
in SC.  PA will injure the ER causing the activation of ER stress genes and an efflux of  
Ca
++
 from the ER into the cytosol.  In euglycemic conditions, lysosomal membrane 
destabilization will follow with the release of cathepsins into the cytosol. Mitochondrial 
damage, increase in ROS and activation of caspase 3/7 ensues.  In hyperglycemic 
conditions, following ER damage, mitochondrial injury, ROS, caspase activation,. 
lysosomal damage and the release of cathepsins is observed   The delay in the lysosomal 
pathway suggests an altered cell death pathway in hyperglycemic conditions. However, 
both pathways lead to apoptosis, thus potentially contributing to the development of 
peripheral neuropathy. PA, palmitic acid; ER, endoplasmic reticulum; Ca
++
, cytosolic 






A closer examination of PA-LTx and its direct or indirect injury to critical cellular 
organelles in the initial stages of apoptosis would be of vast benefit. The understanding of 
early events in PA-LTx may lead to the capability to prevent the full activation of the 
apoptotic pathway and thus inhibiting cell death.  In addition, the role of hyperglycemia 
in PA-LTx and its ability to delay LMD and drive the cell into an earlier and severe 
cellular dysfunction would aid in our attempt to understand the multifactorial aspects of 
diabetic peripheral neuropathy.   In addition, a closer examination in the disruption of 
myelin proteins and the possible additional roles that PMP22 may have in the apoptotic 
process can further aid in the prevention of myelin damage and axonal injury.  
Ultimately, the goal is to explore these finding and extrapolate them into an in 
vivo model.   The female C57BL/6J mouse model has been shown to be a good model 
since mice will develop diabetes base on diet alone.  Mice fed a high fat diet (HFD)( 58% 
fat, 25.6% carbohydrate, and 16.4% protein, total of 12.6 kJ/g) will develop peripheral 
neuropathies which can be examined through nerve conduction velocities and behavioral 
tests: (tactile responses and thermal  analgesia).  Sciatic nerves and lumbar dorsal root 
ganglions (DRGs) from control and HFD animals would be examined using RPTC to 
analyze mRNA levels of ER stress genes and myelin proteins.  Immunohistochemical 
studies would also be performed to analyze the myelin disturbances or nerve disruptions 
that may lead to segmental demyelination and neuropathy.  In addition, in vivo studies 
could also explore the consequences of the reduction in fat in the mice diet and the 
administration of antioxidants (MCI-186) or Ca
++
 chelators (BAPTA-AM) within the 





In conclusion this study demonstrated that SC can undergo LTx in euglycemic 
and hyperglycemic environments with earlier and more severe changes occurring in 
hyperglycemic conditions. The implications of these findings point to the ability of 
circulating elevated levels of LCSFAs to cause Schwann cells injury resulting in SC 
death. The significant dysfunction and decrease in SC viability by LTx may result in the 
disruption of myelin proteins leading to segmental demyelination of axon. The loss of 
myelin, SC-axonal survival interactions and the environment essential for axonal health 
and regeneration, can become a major factor in the development of peripheral 
neuropathy.  In addition, the ability of hyperglycemia to drive the SC into a more severe 
and earlier apoptotic resolution emphasizes the importance in finding a treatment that will 
not only reduce the pain, but will more importantly inhibit neuronal damage and the 
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